

A blue-tinted X-ray of a human chest, showing the rib cage and lungs. Overlaid on the X-ray is a stylized DNA double helix structure, rendered in various shades of blue and green, extending vertically across the lower half of the image. The text "2026" and "LUNG INSTITUTE" is centered in the upper half of the image.

2026 LUNG INSTITUTE

Baylor
College of
Medicine

DIRECTORY OF SERVICES

A	Airway Disease Program	R	Post-COVID Care Clinic
	Upper Airway		Pulmonary Hypertension & CTEPH
	Tracheal Disorders		Pulmonary Rehabilitation
	Asthma		Robotic Cardiothoracic Surgery Center
	COPD		Sleep Medicine Center
	Airway, Voice & Swallowing Center		Systems Onco-Immunology Laboratory (SOIL)
	Laryngologic Dysfunction Clinic		Biorepository
	Dysphagia & Swallowing		Smoking Cessation Clinics
	Subglottic Stenosis		Translational Thoracic Oncology Research La
	Allergy & Immunology		Thoracic & Lung Cancer Program
C	Airways Clinical Research Center (ACRC)	T	Multidisciplinary Care Teams
	Advanced Lung Disease		Medical Oncology
	Interstitial Lung Disease		Pathology
	Pulmonary Fibrosis		Radiation Oncology
	Sarcoidosis		Radiology
	Advanced Lung Support Program		Thoracic Surgery
	ECMO		Interventional Pulmonary Medicine
	Critical Care, ARDS		Tracheobronchoplasty Clinic
	Aspiration, Reflux & Foregut		Trauma-Associated Lung Injury Team
	Bronchiectasis		Undiagnosed Disease Network (UDN)
L	Cystic Fibrosis Center	LUNG INSTITUTE	
	Non-CF Bronchiectasis Program	713-798-5864	
	NTM Program	LUNG TRANSPLANT	
	Chest Wall Resection + Recon Clinic	832-355-9125	
	Congenital Lung Disease Clinic	PULMONARY MEDICINE	
	Concierge Clinic	713-798-2400	
	General Evaluation Clinic	SLEEP MEDICINE	
	(cough & unexplained dyspnea)	713-798-3300	
	Human Genome Sequencing Center	THORACIC SURGERY	
	Genetics	713-798-6376	
P	Genomics		
	Interstitial Lung Disease Research		
	Interventional Pulmonary Service		
	Lung Nodule Clinic		
	Lung Imaging & Ablation		
	Interventional Pulmonary Team		
	Interventional Radiology Team		
	Thoracic Surgery Team		
	Lung Cancer Screening Programs		
	Lung Transplant Program		
P	Palliative Care Program		
	Pediatric Lung & Pulmonology		
	(Texas Children's Hospital)		
	Pleural Disease Program		
	Endometriosis		
	Mesothelioma Treatment Center		
	Benign Pleural Disease		

DIRECTOR'S MESSAGE

The Baylor College of Medicine Lung Institute is dedicated to advancing comprehensive lung care through community engagement, research, innovation, and education. Our focus on prevention of disease brings all disciplines together working towards a singular goal. This has already been a highly productive year. With more than 300 members across seven hospital locations, the Institute includes more than 50 multidisciplinary specialty clinics and centers of excellence focused on a wide range of pulmonary conditions. Our physicians, researchers, surgeons, and administrative teams are internationally recognized leaders in lung disease. Together, we are committed to delivering exceptional, patient-centered care and advancing the future of pulmonary and thoracic medicine. It is truly an honor to lead such a distinguished and collaborative group of specialists. In the year ahead, we will continue to build on this momentum by enhancing scholarship opportunities, expanding co-located services, and improving patient navigation across and within our programs.

Shanda Haley Blackmon, M.D., M.P.H.
Professor of Surgery
Olga Keith Wiess Chair of Surgery III
Director, The Lung Institute
Baylor College of Medicine





Director and Co-Director of the Baylor College of Medicine Lung Institute, Drs. Shanda Blackmon and Nirmal Sharma are poised to lead initiatives to advance treatments for lung disease.

Our Promise

Patients are at the heart of everything we do.

To us, this means delivering individualized cutting-edge diagnosis and treatment in a compassionate manner to each individual. Our patients have access to the latest advances in medicine thanks to close collaborations between our physicians and scientists.

The Lung Institute team is committed to delivering excellent and highly specialized patient care by using the latest technology and research to diagnose and effectively treat patients with complex lung disease. Through innovation, research and excellence in clinical care, we offer patients unique access to new diagnostic and therapeutic modalities. Our specialized team is dedicated to our patient's health both in the hospital setting and in clinic. This individual approach provides our patients with the security of knowing they are receiving treatment that is advanced, minimally invasive, with the proper follow-up care.

Mission

At the Lung Institute we aim to advance lung knowledge, discovery, intervention and education to best serve the nation and the world in the 21st century. We provide the Baylor College of Medicine community with advice, tools and resources to facilitate excellence in lung health.

Vision

As experts in lung health, we aspire to provide exceptional service to Baylor College of Medicine's patients, schools, centers, affiliated hospitals & clinics, research programs, affiliated industry partners and learners that enable Baylor to pursue extraordinary opportunities and achieve their patient care, research, teaching, innovation and learning goals.



Lung Institute Faculty and Staff

Director
Shanda Blackmon, M.D., MPH

Co-Director
Nirmal Sharma, M.D.


Administrative Lead
Stephanie Middleton

Steering Committee:
Philip Alapat, M.D.
Tara Lynn Barto, M.D.
Ramiro Fernandez, M.D.
Shawn Groth, M.D.
Nicola Alexander Hanania, M.D.
Farrah Kheradmand, M.D.
Gabriel Loor, M.D.
Prasad Manian, M.D.
Dawn Marshall
Stephanie Middleton
Sarah Morrissey, NP
Francesca Polverino, M.D., Ph.D.
Ivan O. Rosas, M.D.
R. Taylor Ripley, M.D.
Nirmal Sharma, M.D.
Javeryah Safi, M.D.
Fidaa Shaib, M.D.
Subin Valayil, PA

Operations Manager
Dawn Marshall

Research coordinators
Erick A. Carrasco Barcenas, M.D.
Monica Vilchis
Anna Castillo

Lung Operations Committee:
Shanda Blackmon, M.D., MPH
Erick A. Carrasco Barcenas
Rebecca S. Grubb
Gabriel Loor, M.D.
Elsa Lozano
Dawn Marshall
Marinna Melchor
Stephanie Middleton
Nicole Jawanmardi Miller
Ivan O. Rosas, M.D.
Nirmal Sharma, M.D.
Holly Church Shilstone
Enrique Serrano
Hunter Snyder, MHA
Nikkie N. Taylor
Cyrus Vahdatpour, M.D.
Subin Valayil, PA-C



The Baylor College of Medicine Lung Institute divides focus into four pillars of influence; Healthcare/Clinical Practice, Research & Innovation, Education, and Community Engagement.

Lung Institute Leadership Positions and Pillar Champions

Healthcare Champions

Gabriel Loor, M.D.
Cyrus Vahdatpour, M.D.
Xiaoming Guan, M.D.

Education Champions

Philip Alapat, M.D.
Subhasis Chatterjee, M.D.
Nicola Alexander Hanania, M.D., MS

Research and Innovation Champions

Nirmal Sharma, M.D.
Francesca Polverino, M.D., Ph.D.
Ramiro Fernandez M.D.
Livia S. Eberlin, Ph.D.

Community Engagement Champions

Farrah Kheramundi, M.D.
Subin Valayil, PA
Roger Zoorob, M.D., MPH
Tara Barto, M.D.



On Air, a podcast hosted by Dr. Shanda Blackmon, features real patient stories, expert insights, and the latest advancements in thoracic surgery and lung care.



The Lung Institute Podcast videos are now available on the Baylor College of Medicine YouTube Channel. There have been more than a thousand downloads. Membership for regular subscriptions are available.

Follow us on X @BCMLunginst




RESPECT
Integrity
INNOVATION
Teamwork
Excellence

THE LUNG INSTITUTE
(713) 798-5864

Baylor College of Medicine
Baylor St. Luke's McNair Campus
Baylor St. Luke's Medical Center
Harris Health Ben Taub Hospital
Jamail Specialty Care Center
Lillie & Roy Cullen Health Sciences Tower
Texas Children's Hospital


Not Pictured:
Kirby Glenn Center
Sugar Land Clinic for Baylor Medicine
The Woodlands Clinic for Baylor Medicine




Baylor College of Medicine

FACULTY


STAFF



TRAINEES




ALUMNI*





The Lung Institute

THE LUNG INSTITUTE IS MADE UP OF MORE THAN 300 PHYSICIAN MEMBERS



THE LUNG INSTITUTE BY THE NUMBERS





Healthcare


Baylor’s private adult practice, Baylor Medicine, includes nationally and internationally recognized physician experts and care teams, offering an array of services from primary care to highly specialized procedures. Our physicians care for patients in locations within the Texas Medical Center as well as other Houston areas.

- Baylor St. Luke’s Medical Center
- Harris Health Ben Taub Hospital
- Central Texas Veterans Healthcare System, Temple, Texas
- The Institute for Rehabilitation and Research (TIRR) Memorial Hermann
- The Menninger Clinic
- Michael E DeBakey Veterans Affairs Medical Center
- Texas Children’s Hospital




(713) 798-1000

Pulmonology Clinic Volume




The Section of Pulmonary Medicine continues to see more than 10,000 patients every year in clinic.

Otolaryngology Total Volume



The Department of Otolaryngology continues to see more than 6,000 patients every year.

Pulmonology Case Volume



Pulmonary medicine specialists provide care in more than seven hospitals across Houston. Within the Baylor St. Luke’s Medical Center, the interventional pulmonologists perform more than 300 procedures, including bronchoscopy, endobronchial ultrasound, rigid bronchoscopy, bronchoscopic stenting, and dilations of the airway.

*Projected



Research and Innovation

Baylor College of Medicine received \$687 million in total funding from 2,792 sponsored project awards in fiscal year 2023.

The College ranks #19 among all U.S. medical schools for NIH funding and #8 in the nation by the National Science Foundation for research expenditures in biological and biomedical sciences. *U.S. News & World Report* has named Baylor College of Medicine a Tier 1 medical school for research.

The scale of Baylor's research enterprise, the exceptional caliber of faculty we attract and the richness of biomedical research resources within the Texas Medical Center support creativity innovation and discovery

Select Funded Lung Research



Francesca Polverino, M.D., Ph.D.
Lester and Sue Smith Professor of Medicine
Baylor College of Medicine

Dr. Polverino leads the COPD Translational Research Program. A physician-scientist, her clinical and research interests center on the pathogenesis and developmental origins of chronic airway diseases, with a focus on the genetic, genomic, and developmental determinants of individual susceptibility to cigarette smoke.

After completing medical school and residency in Italy, she joined Harvard Medical School in 2010, where she completed her PhD and later joined the faculty in 2015. Over the course of her career, she has received numerous prestigious honors, including the COPD Gold Medal from the European Respiratory Society, the Medal of Honor for Scientific Merit from the President of the Italian Republic, and the Parker B Francis Award from the American Thoracic Society.

Dr. Polverino has published over 140 peer-reviewed papers and serves as Principal Investigator on several NIH and foundation-funded projects. She is also a national medical spokesperson for the American Lung Association, where she advocates for awareness, prevention, and treatment of chronic lung diseases.

IN FUNDING FROM THE NATIONAL INSTITUTES OF HEALTH

BAYLOR RANKS

19TH

IN THE NATION

1ST

IN TEXAS SINCE 2006

8 DEPARTMENTS RANK IN THE TOP 20 IN RESEARCH FUNDING FROM NIH, INCLUDING A #1 RANKING IN GENETICS, WHICH HAS HELD THIS POSITION SINCE 2011.

OUR FACULTY INCLUDES

2

**HOWARD HUGHES MEDICAL
INSTITUTE INVESTIGATORS**

5

**MEMBERS OF THE NATIONAL ACADEMY
OF SCIENCES**

7

**MEMBERS OF THE NATIONAL ACADEMY
OF INVENTORS**

13

**MEMBERS OF THE NATIONAL ACADEMY
OF MEDICINE**

24

**FELLOWS OF THE AMERICAN ASSOCIATION
FOR THE ADVANCEMENT OF SCIENCE**

21


**MEMBERS OF THE ASSOCIATION OF
AMERICAN PHYSICIANS**

61

**INDIVIDUALS WITH NIH CAREER
DEVELOPMENT AWARDS**



Drs. Amani Zoubi, Yasmin Shanneik and Brant Wang work together to test the MasSpec Pen on a lung tumor that has been removed by Dr. Shanda Blackmon. Real-time testing in the lab to develop novel tools to enhance the science of lung cancer care in action at Baylor St. Luke’s Medical Center.



Drs. Yaxin Wang, Chris Chan and Gabriel Loor

A New Approach to Organ Preservation

The technology at the center of this innovation is called ex vivo lung perfusion (EVLP), a method that keeps donor lungs functioning outside the body by circulating fluids and gases through them, simulating real-life conditions.


The new system created by The Texas Heart Institute at Baylor College of Medicine team takes EVLP a step further. Unlike traditional methods that offer limited support and transport time, this platform uses enhanced circulation, ventilation, and incubation features to mimic the human body more accurately. That means better preservation, more time to transport the organ safely across greater distances, and even the possibility to treat and improve lungs while they are en route.

“This isn’t just about buying more time,” explains Dr. Wang. “It’s about giving surgeons healthier lungs to work with—and ultimately giving patients a better chance at survival and recovery.”



Amy Wood, Monica Vilchis, C.C.R.P., , Erick A. Carrasco, M.D., and AnnaMaria Castillo, B.S., represent the Thoracic Surgery and Lung Institute Research Team. They help with protocol development, IRB communication, thoracic oncology working group collaboration, Dan L Duncan Comprehensive Cancer Center collaboration, grants, databases, consent patients for research, collect specimens and coordinate services with the HTAP (Human Tissue And Pathology) department to store specimens for research.






Mudassir Banday Ph.D., Yasufumi Goda M.D. Ph.D. ,Prangthip Charoenpong M.D. and Nirmal S. Sharma M.D.

Dr. Nirmal Sharma, co-director of the Baylor College of Medicine Lung Institute, leads research through the ALOFT Lab, which is an NIH-funded basic-translational research laboratory dedicated to improving outcomes for patients with advanced lung disease and lung transplantation. The laboratory focuses on understanding why lung allografts (lungs that have been transplanted) fail and how early immune, microbial, epithelial, and vascular injury can be detected, prevented, and treated. Essentially, looking for novel ways to make tranplanted lungs last longer.

A defining feature of the ALOFT Lab is its use of integrated translational models that connect patient-centered research with mechanistic discovery. We study human lung transplant recipients through biospecimens, clinical phenotyping, biomarker studies, and outcomes research, while also using murine lung transplant models, precision-cut lung slices, ex vivo lung perfusion, and emerging lung organoid systems to define causal pathways of injury and test future therapeutics.



IAV induces fibrogenesis via IRF7-IL33-MMP9 axis. Banday et al. *Ebiomedicine* 2026

ALOFT Lab research spans acute rejection, chronic lung allograft dysfunction, regulatory T-cell dysfunction, interferon-mediated lung injury, epithelial repair, microbial dysbiosis, and biomarker-based approaches to earlier detection of allograft injury. By integrating human cohorts with experimental platforms, the ALOFT Lab aims to move beyond association and identify actionable mechanisms that can be translated into precision therapies.

Embedded within the Baylor Lung Institute and closely aligned with the lung transplant and advanced lung disease programs, the ALOFT Lab is committed to patient-centered research that improves survival, quality of life, and long-term outcomes for lung transplant recipients and patients with advanced lung disease.

Research themes: lung allograft rejection; lung fibrosis; chronic lung allograft dysfunction; regulatory T-cell biology; host-microbiome interactions; epithelial and vascular injury; murine lung transplantation; precision-cut lung slices; lung organoids; translational biomarkers; patient-centered outcomes; and future therapeutics.

Scholarships Awarded by the Lung Institute - 2026



The Lung Institute is proud to recognize the recipients of its 2026 Grant Scholarship Awards, supporting innovative projects in research, clinical practice, education, and community engagement that advance lung health and patient care.



Clinical Practice – Healthcare

Cyrus Vahdatpour, M.D. and Ajith Nair, M.D.
Level 3 CPET Program Development: Provider Training Initiative

Gloria Li, M.D.
My Pulmonary Portal: A Virtual Pulmonary Rehabilitation App to Improve Patient Outcomes in Pre- and Post-Lung Transplant Recipients



Research & Innovation

Ahmed Hamdi, M.D.
Strengthening Multidisciplinary Collaboration and Research Productivity in Pulmonary NTM Care at Baylor

Cyrus Vahdatpour, M.D.
Pericyte-Endothelial Signaling Disruption as a Mechanism of Right Ventricular Microvascular Injury in Group 2 Pulmonary Hypertension

Prangthip Charoenpong, M.D., M.P.H.
Pulmonary Hypertension in Chronic Lung Allograft Dysfunction: A National Analysis Using the Scientific Registry of Transplant Recipients Database

Lavannya M. Pandit, M.D., M.S.
Comparative Transcriptomic Profiling of Acute and Chronic Thrombi to Identify Prognostic Biomarkers in CTEPH Development



Education

Nicola Hanania, M.D., M.S; Muhammad Adrish, M.D., M.B.A.; Michael Fordis, M.D.
Advances in Pulmonary Medicine 2026 Conference: A Regional Educational Initiative to Enhance Clinical Competence and Collaboration in Lung Health



Community Outreach

Chao He, M.D., Ph.D.
Respiratory Health in Houston Firefighters: Establishing a Longitudinal Program to Safeguard Firefighter Health

Muhammad Khyzar Hayat Syed, M.D.
Enhancing Support and Multidisciplinary Care for Pulmonary Fibrosis Patients through Patient-Caregiver Support Groups and Community Physician Engagement in ILD MDD Conferences

Selected Funded Research Projects within Baylor College of Medicine Related to Pulmonary Science

1. Pathophysiology of Vascular Remodeling in Pulmonary Hypertension
2. Cell-Based Immunomodulation to Suppress Lung Inflammation and Promote Repair
3. Macropinocytosis and Pulmonary Fibrosis
4. Multi-omic Investigation of Drivers of Systemic Lupus Erythematosus
5. Let-7 microRNA in Lung AT2 Cell Homeostasis and Regeneration
6. Cadherin-11 in Development and Treatment of Lung Fibrosis
7. Baylor College of Medicine Respiratory Research Training
8. Transcriptional Regulatory Knowledgebase of Pulmonary
9. Ex Vivo Lung Perfusion Organ Reconditioning
10. Porcine Model of Ascaris-Induced Chronic Lung Disease
11. Delineating the Role of LET-7 Microrna on Lung AT2 Cell Homeostasis, Alveolar Regeneration, and Interstitial Lung Disease
12. Understanding Adherin-11 in the Development and Treatment of Lung Fibrosis
13. Eliminating Monitoring Overuse
14. Early Life Exposures and Chronic Lung Disease
15. Hyperpolarized 129Xe MRI for Lung Function
16. Genetic Epidemiology of COPDGENE® 10.0
17. Early Life Exposures and Chronic Lung Disease
18. Tumor Antigens in Lung Cancer Initiation and Progression
19. B Cell Adaptive Immune Profile in A1-AT Deficiency-Associated Emphysema
20. Service Agreement with American Cancer Society Biomarker Echo Lung Cancer Project
21. Airways Clinical Research Centers (ACRC) Network Databank
22. Project Extension: The American Lung Association Lung Health Cohort
23. Protective Effects of Metformin Against AT2 Cell Dysmetabolism In COPD
24. Competing Continuation: Year 3- SHP2 Inhibits SKP2-Targeted Ubiquitination of TBET in Severe Sarcoidosis
25. A Transcriptional Regulatory Knowledgebase of Pulmonary Fibrosis at Single Cell Resolution
26. 2025-2026: Care Center Grant; Awardee Id: Cc012-Ad
27. Implementation of Outpatient CF Pharmacy Services
28. Program for Adult Care Excellence (PACE) Award
29. Advancing the Quality of Care for Post-Transplant Cystic Fibrosis Patients
30. Extracellular Matrix Characterization of Fibrotic and Non-Diseased Lungs
31. Baylor College of Medicine Long-COVID Model System of Care Serving the 29th Congressional District of Texas
32. CTSA K12 Program at Baylor College of Medicine and University of Houston
33. Collaborative Research Training in Thrombosis and Inflammation
34. B Cell-Adaptive Immune Profile in Emphysema-Predominant COPD
35. Baylor College of Medicine-Respiratory Research Training
36. Mechano-signaling Regulates Macrophage Immunometabolism: Assist 1814293
37. Hyperpolarized 129xe MRI to Identify Structural Determinants of Low Lung Function and Respiratory Symptoms in Young Adults From the Lung Health Cohort
38. Clinical Genetics and Screening for Pulmonary Fibrosis
39. Sineoculis Homeobox Homolog 1 (Six1) in Pulmonary Fibrosis
40. Insulin Resistance, Pre-Diabetes, and Diabetes in Obesity-Associated Asthma
41. Noradrenergic Mechanisms of Interstitial Pulmonary Fibrosis
42. Clinical Validation Center for Lung Cancer Early Detection
43. Metformin In Asthma for Overweight and Obese Individuals
44. Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (Copdgene® 10.0)
45. 1/2 Precision Ventilation to Attenuate Ventilation-Induced Lung Injury (Prevent Vili)
46. Preparation for Lung Transplant Discussions And Decisions Among People with Cystic Fibrosis
47. Repurposing of FDA-Approved Nrf2 Activators as A Novel Inhaled Therapy for Fibrosis
48. Exploratory Role of the Cytoskeleton in Anisotropic Regulation of Micrnas in Skeletal Muscles
49. Collaborative Research: Mathematical Modeling of Respiratory Muscles
50. Collaborative Research: The Interaction of Surfaces Structured at the Nanometer Scale With the Cells in the Physiological Environment.
51. Therapeutic Potential Of Targeting Dkk1 In COPD - Pathways Grant
52. Predictors of De-Novo Development of OSA In Pregnancy






Education

The Lung Institute is committed to advancing lung health education by equipping learners and healthcare professionals with the knowledge, tools and resources needed to improve care locally and globally.

The Michael E. DeBakey summer students spent time shadowing the thoracic surgery service learning about complex airway and pulmonary disease. They were able to participate in rounds, teaching and discussions.



The Thoracic Surgery Integrated Residency, Thoracic Surgery Fellowship, and Cardiac Transplant Surgery Fellowship training programs graduated four surgeons this year from Baylor College of Medicine. The training program also graduated one advanced fellow who trained with advanced experience in mechanical circulatory support and lung transplantation. This represents just a fraction of the educational programs that are offered from Baylor College of Medicine.

EDUCATION ▼

Baylor College of Medicine educates healthcare providers and scientists in programs considered among the elite in the world.

Degree programs at Baylor include:

- M.D. program
- Dual degree programs (M.D. plus Ph.D., M.B.A., M.P.H., J.D. or M.S.)
- Ph.D. programs
- A doctoral program in nurse anesthesia
- A physician assistant program
- An orthotics and prosthetics program
- A genetic counseling program

A diploma course in tropical medicine prepares individuals interested in this growing field for certification.



One of the residents in the current thoracic surgery training track, Christopher Strader, M.D., MPH, prepares to dock the robot for advanced surgical training.



Justin Segraves M.D.
Director, Lung Transplant and ALD
Fellowship Program

“Our fellowship prepares you not just for a job, but for a career where you can lead, innovate, and make a real impact in pulmonary medicine.”

Lung Transplant Medicine Fellowship

Overview

We strive to meet patient needs through innovative research, cutting-edge technology, and providing high-quality and compassionate healthcare. The Baylor St. Luke’s lung transplant program was established in 2008, and through steady growth has become an established referral center for patients with advanced irreversible lung disease. We have performed the greatest number of transplants in Texas in the past 1- and 3-year periods, and we are in the top 5 program by volume in the USA with exemplary patient outcomes, which underscores our commitment to quality patient care.

Why Train With Us?

High-Volume Lung Transplant Center: >100 transplants per year
World-Class Medical Center: Training at the largest medical center in the world

Areas of specialty

Extra Corporeal Membranous Oxygenation (ECMO) bridge to transplant program
Multi-organ transplants (heart-lung, liver-lung, kidney-lung)
Redo lung transplants



Donation after cardiac death (DCD) program

Organ preservation program including ex vivo lung perfusion (EVLP) organ procurement.
*1st program in Texas to perform EVLP lung transplant in 2018
Flexible Curriculum: Tailor your fellowship toward lung transplant, advanced lung disease, pulmonary hypertension, ICU care, or a hybrid practice
Career-Ready Mentorship: Graduates leave prepared for diverse, cutting-edge careers

Program Highlights

1 Fellow Accepted Per Year – Personalized mentorship and guidance
Hands-On Training: Extensive exposure to lung transplantation and complex pulmonary care

Alumni Spotlight

Brittany Duong, current fellow, joins faculty in August 2026
Splitting her practice 75% lung transplant, 25% ICU per her preference
Incoming Fellow: Ruhma Ali, starting July 2026

Who Should Apply?

Ideal for physicians in pulmonary and critical care medicine seeking:
Advanced expertise in lung transplant and complex lung disease
Training for a hybrid career combining transplant, ICU, and specialized pulmonary care
Apply or Learn More, email: justin.segraves@bcm.edu




Thoracic Nurse Master Course




The Lung Institute is partnering with our nursing communities across all of the hospitals we serve to bring value in advanced education programs to elevate the care of patients with lung disease.

Somi Mathew, MSN, RN who is one of the Baylor St. Luke’s Medical Center nursing floor managers, teaches a nurse to follow the Thoracic Master Class Curriculum, developed by the Lung Institute Team. Nurses can take these classes and become certified Thoracic Masters in their field. This equips them to be more prepared to care for complex thoracic patients within the hospital and drives improved outcomes.



The ERAS, enhanced recovery after surgery, pathway developed on a national CommonSpirit level, was initiated at Baylor St. Luke’s and resulted in a decrease in length of stay among patients undergoing lung resection within the hospital setting. The graphic above is an example of the pathway that was used to improve care.



On Saturday, Feb. 21, 2026, the expert faculty of the Lung Institute gathered together to deliver a series of expert lectures on advances in pulmonary medicine. The topics ranged from “Managing Non-tuberculous Mycobacterial Infections” to “Managing Pleural Effusions”

Directors:
Nicola Hanania, M.D., M.S.
Muhammad Adrish, M.D.

Co-Directors:
Lavanya Pandit, M.D.
Gloria Li, M.D.

Advisory Committee:
Ivan Rosas, M.D.
Farrah Kheramundi, M.D.
Rolando Rumbaut, M.D.
Shanda Blackmon, M.D, M.P.H.

Faculty:
Fatima Adhi, M.D.
Muhammad Adrich, M.D.
Sandeep Bahour, M.D.
Shanda Blackmon, M.D., M.P.H.
William Brasher, M.D.

Prangthip Charenpong, M.D., M.P.H.
Sunjay Devarajan, M.D.
Elizabeth Guy, M.D.
Nicola Hanania, M.D., M.S.
Muhammad Hayat, M.D.
Christina Kao, M.D.
Farrah Kheradmand, M.D.
Adam Kley, M.D.
Donald Lazarus, M.D.
Gloria Li, M.D.
Babith Mankidy, M.D.
Lavannya Pandit, M.D.
Francesca Polverino, M.D.
Suhall Raoof, M.D., M.A.C.P., Master F.C.C.P.
Katherine Richards, M.D.
Ivan Rosas, M.D.
Rolando Rumbaut, M.D.
Javeryah Safi, M.D.
Sandeep Sahay, M.D.
Gautam Sikka, M.D.
Tinashi David Wu, M.D.

The Lillie and Roy Cullen Tower

Baylor College of Medicine is one of the nation's premier academic medical centers and a cornerstone institution within the Texas Medical Center. Founded in 1900 and relocated to Houston in 1943, Baylor has developed an international reputation for excellence in medical education, biomedical research, and patient care. The institution is affiliated with many of the country's leading hospitals, including Texas Children's Hospital, Baylor St. Luke's Medical Center, Ben Taub Hospital, and MD Anderson Cancer Center, providing students and trainees exposure to one of the most diverse and clinically complex patient populations in the world. Baylor is widely recognized for its accelerated medical curriculum, strong NIH-funded research enterprise, and leadership in fields ranging from cardiovascular surgery and genomics to cancer biology, infectious disease, and regenerative medicine.

A state-of-the-art medical education facility opening in 2026

The institution is now entering a transformative new era with the construction of the Lillie and Roy Cullen Tower, a next-generation health sciences education building scheduled to open in 2026. Located adjacent to Helix Park in the Texas Medical Center, the 11-story, approximately 503,000-square-foot tower will be one of the most technologically advanced medical education facilities in the United States. Designed to integrate education, research, and clinical collaboration, the building will feature immersive simulation centers, advanced anatomy and teaching laboratories, collaborative small-group learning spaces, computational research areas, and large high-tech lecture venues. The tower is the first phase of Baylor's broader Health Sciences Park initiative, which aims to create a collaborative ecosystem uniting biomedical innovation, patient care, biotechnology partnerships, and medical education in a single integrated campus.

The Cullen Tower



Nearly 300 students from the School of Medicine, the Genetic Counseling Program in the School of Health Professions and the Graduate School of Biomedical Sciences graduated from Baylor College of Medicine on May 21, 2026. According to *US News & World Report*, Baylor College of Medicine is a Tier I Best Medical School in Research.



Community Engagement

Baylor College of Medicine partners with local leaders to serve the communities of Houston and the world through:

- Baylor global health
- Baylor global initiatives
- Healthcare for the homeless
- Houston shoulder to shoulder
- Community health clinics
- School based clinics
- Teen health clinics

Research designed to develop new approaches to prevention diagnosis and treatment that fulfill specific community needs including

- Center for Medical Ethics and Health Policy
- Center for Precision Environmental Health
- Children's Nutrition Research Center
- The Dan L Duncan Institute for Clinical and Translational Research
- National School of Tropical Medicine
- Office of Outreach and Health Disparities of the Dan L Duncan Comprehensive Cancer Center
- Undiagnosed disease network

Education outreach programs that help every student to achieve their full potential including

- 3 middle schools and 9 high schools
- 4 BS/MD programs
- Bio Ed online
- Teacher professional development programs
- Programs designed to promote diversity in medicine and biomedical research
- GRAB (Grocery Resource at Baylor), a food pantry for Baylor students

Baylor St. Luke's Medical Center
PULMONARY FIBROSIS SUPPORT GROUP



LIVING WITH PULMONARY FIBROSIS

An Interview with
LEE FOGLE

Tuesday, May 5th
12:00 PM CDT

Join on Google Meet
<https://meet.google.com/owii-uxcd-zni>
Or dial: (US) +1 401-646-0660
PIN: 642 713 237#

Join us for an inspirational interview and support!



The Baylor College of Medicine Lung Institute was proud to sponsor multiple surgical and medical society meetings over the past year. Our focus remains on engaging academic partners and fostering collaboration. By maintaining a strong presence at national and regional meetings, the Lung Institute connects providers with leading scientific communities and advances multidisciplinary research and interventions.

American Lung Association

The Lung Institute has several leaders who also serve on the Board of Directors of the American Lung Association. Both Dr. Shanda Blackmon and Dr. Gabriel Loor have played a role in helping the American Lung Association promote local events and raise awareness about lung health.



Drs. Shanda Blackmon, Lauren Barron, Anna Xue, Jennifer Cozart, and Lorraine Cornwell represented the Baylor College of Medicine Lung Institute this year.



KOPPA

The 76th Annual KOPPA (Kando O. Pulmonary Physicians Association) Conference will take place from July 31 to August 1, 2026, at the historic Mo-Ranch Conference Center in Hunt, Texas. The event focuses on state-of-the-art lung updates for pulmonologists, thoracic surgeons, and allied healthcare professionals. Baylor College of Medicine Lung Institute will be exhibiting at the annual KOPPA Conference this year.



Dr. Gabriel Loor, Dr. Ramiro Fernandez, Dr. Shanda Blackmon and colleagues presented at the National ACCP CHEST meeting in Chicago this past year, where the Baylor College of Medicine Lung Institute had a booth. We raised awareness of the available resources from the Institute and participated in round table events as well as presented formal invited talks.



National Smoke-out day celebrated in the Baylor St. Luke's lobby with education for patients and staff


During Lung Cancer Awareness Month in November, Drs. Ivan Rosas and Nirmal Sharma helped to raise awareness about the damage from smoking at the national Smoke Out Day celebration on the McNair Campus of Baylor St. Lukes Medical Center.



Cystic fibrosis is a genetic disorder that affects the lungs, pancreas, and other organs. The Cystic Fibrosis Foundation is the world's leader in the search for a cure for CF and supports a broad range of research initiatives to tackle the disease from all angles. The CF Foundation is the world's leader in the fight against CF, and our scientific portfolio reflects our drive to provide effective treatments and — one day — a cure to every individual with this disease. Genetic therapies have the potential to work for any person with CF, regardless of their CFTR mutations. This includes people who don't qualify for CFTR modulators or can't take them for any other reason.



As Houston's only Cystic Fibrosis Foundation accredited adult care center, The Baylor Medicine Maconda Brown O'Connor, Ph.D., Adult Cystic Fibrosis Center is one of the largest in the United States and provides clinical care to the patients 18 years and older with cystic fibrosis in a multidisciplinary manner including providers, nursing, nutrition support, social services and respiratory therapy focused on this disease process. Additionally, we offer opportunities to participate in clinical trials ranging from observational to interventional (Phase I-IV) options.



The American Lung Association generates the *State of Lung Cancer Report* yearly. More people than ever are surviving lung cancer. The Lung Institute is partnering with the Dan L Duncan Comprehensive Cancer Center to help raise awareness and impact our lung cancer community.

Our Vision Is a World Free of Lung Disease

"Together, we can save lives by improving lung health, preventing lung disease, and creating a healthy world for all." The Baylor Medicine Lung Institute is aligned with the American Lung Association.



Stand with LUNG FORCE to Defeat Lung Cancer

Only a force of many can take on lung cancer—the #1 cancer killer in America. LUNG FORCE unites us to stand together and save lives. Baylor College of Medicine Lung Institute is partnering with the American Lung Association and Lung Force to make a difference in your community.



Support from the Community



Philanthropy plays a critical role in Baylor College of Medicine’s quest to accelerate research programs and to bolster the activities of our educators, our learners and our ability to provide leading-edge patient care for our Houston and other communities. In 2023, supported by an engaged Board of Trustees and Board of Advisors, a global network of alumni and volunteers, Baylor received more than 6,900 gifts and raised more than \$113 million in new gifts and commitments.

The Baylor College of Medicine Lung Institute is supported by many grateful patients and donors within our community. These funds, grants and support from the college enable the Institute to bring scientific investigators together and benefit our community of learners, investigators and patients.

A gift from Lester & Sue Smith was used to establish the Thoracic Surgery Clinic, which is located on the 6th floor of the new Baylor McNair Campus offices. This fund was also used to facilitate many of the initiatives for the Lung Institute.

Make a Gift

Your gift to the Lung Institute will help pioneer new procedures and technologies, advance medical research, improve the quality of patient care and train the next generation of surgeons, educators and innovators. Thank you for your generosity.



Cystic Fibrosis Center



Tara Lynn Barto, M.D., MSCR
Assistant Professor
Director, Baylor Adult Cystic Fibrosis Program
Section of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine

“I strive to provide state of the art, compassionate, comprehensive, care to the adult cystic fibrosis community as well as those with complex pulmonary diseases including non-cystic fibrosis bronchiectasis.”

As Houston’s only Cystic Fibrosis Foundation accredited adult care center, The Baylor Medicine Maconda Brown O’Connor, Ph.D., Adult Cystic Fibrosis Center is one of the largest in the United States and provides clinical care to the patients 18 years and older with cystic fibrosis in a multidisciplinary manner including providers, nursing, nutrition support, social services and respiratory therapy focused on this disease process. Additionally, we offer opportunities to participate in clinical trials ranging from observational to interventional (Phase I-IV) options.

Baylor Medicine | cysticfibrosis@bcm.edu | 713-798-2400

Advanced Lung Support Program

ARDS, ECMO & Critical Care



Subhasis Chatterjee, M.D.
Associate Professor
Division of Trauma and Acute Care Surgery
Division of Cardiothoracic Surgery

Director, Thoracic Surgical ICU & ECMO Program
Baylor St. Luke's Medical Center




Our ECMO Program brings together a multidisciplinary team of more than 30 physicians—including cardiothoracic surgeons, interventional cardiologists and intensivists—who work in close collaboration with nurses, perfusionists, physical therapists and advanced practice providers to optimize outcomes for patients requiring extracorporeal life support.

We utilize ECMO as a bridge to recovery or to definitive therapies such as organ transplantation or durable mechanical circulatory support. Our team is actively engaged in clinical trials, regularly publishes in peer-reviewed journals, and shares its expertise at national and international conferences. We are also committed to training the next generation of physicians in advanced ECMO management.



ECMO case volume - Baylor St. Luke's Medical Center



Baylor St. Luke's Medical Center has consistently increased the number of patients supported with ECMO (ExtraCorporeal Membrane Oxygenation). This form of lung support is available to patients when a traditional ventilator may not be enough. During 2025, over 200 patients were supported with this technology.

Patients managed by ventilator - Baylor St. Luke's Medical Center

	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cases	2,699	2,519	2,414	2,607	2,635	2,719
Days on Ventilator	16,519	19,017	17,494	17,306	17,659	17,947

Baylor St. Luke's Medical Center consistently manages some of the most complex patients in the medical center and maintains consistent high volume both in the number of patients supported by a ventilator and in the numbers of days on a ventilator.

Airway Disease Program



Nicola Alexander Hanania, M.D., MS
Professor, Medicine-Pulmonary
Director, Airways Clinical Research Center
Baylor College of Medicine

Chief, Pulmonary/Critical Care/Sleep Medicine
Ben Taub Hospital

“My ultimate goal is to improve the outcome of patients with asthma and COPD not only by providing state of the art evidence-based care, but by developing and testing new interventions to eliminate burden of these diseases.”

The Baylor Medicine Airway Disease Program provides comprehensive services for all patients with asthma and chronic obstructive pulmonary disease (COPD). We offer the full spectrum of conventional and advanced therapies for patients through compassionate patient-centered care, education and self-empowerment. We partner with allergy and immunology, otolaryngology, interventional pulmonology and thoracic surgery experts to ensure patients have a treatment plan that considers all aspects of their condition.

- Severe and steroid-dependent asthma
- Allergic and eosinophilic asthma
- Non-allergic asthma
- Asthma in high-risk groups, including pregnancy
- Aspirin-exacerbated respiratory disease
- Allergic bronchopulmonary aspergillosis
- Advanced chronic obstructive pulmonary disease (COPD)
- Chronic bronchitis and emphysema
- Chronic cough



Research:

The Airway Disease Program is one of the sites of the Baylor Airways Clinical Research Center (ACRC). Patients participate in clinical studies which are advancing how we treat asthma and COPD.



Baylor Medicine at McNair Campus
7200 Cambridge St. Suite 8A
Houston, TX 77030
Fax: (713) 873-3346
(713) 798-2400


Airways Clinical Research Center



The ACRC Network is a jewel in the crown of the American Lung Association research program. As the nation's largest not-for-profit network of clinical centers dedicated to asthma and COPD research, it includes an impressive bandwidth of experts working together to produce results directly affecting patient care. The ACRC Network positively impacts patients through large patient-focused clinical trials led by some of the best investigators nationwide.

The local Airways Clinical Research Center at Baylor College of Medicine is part of Asthma Clinical Research Centers, a nationwide clinical network created by the American Lung Association and is the only center in Texas. The principal investigator of the Baylor ACRC is Nicola A. Hanania, M.D., of the pulmonary section of the Department of Medicine. The co-principal investigator is Marianna M. Sockrider, M.D., Dr.PH, of the pediatric pulmonology section of the Department of Pediatrics. The center includes several other investigators from Baylor St. Luke's Medical Center, Houston Methodist Hospital, Ben Taub Hospital and Texas Children's Hospital and is part of the Biology of Inflammation Center.

Advanced Lung Disease Clinic



Baylor St. Luke’s Medical Center, The Center for Advanced Lung Disease and Transplantation provides cutting-edge care for a wide range of progressive lung diseases that require specialized treatments, including but not limited to lung transplantation. Sub specialists provide multidisciplinary care under one roof, focusing on patient-centered approaches to diagnose and treat progressive lung diseases. We specialize in treating common disorders, as well as rare genetic pulmonary disorders like Hermansky-Pudlak Syndrome, lymphangioleiomyomatosis (LAM) or alpha-1-antitrypsin deficiency, which can also be associated with progressive decline in lung function.

- Interstitial lung disease
- Pulmonary fibrosis
- Sarcoidosis
- Connective tissue diseases
- Autoimmune lung diseases
- Chronic Obstructive Pulmonary Disease (COPD)
- Emphysema
- Pulmonary hypertension
- Hermansky-Pudlak syndrome
- Langerhans cell histiocytosis
- Lymphangioleiomyomatosis (LAM)
- Birt hogg dube syndrome
- Alpha-1-antitrypsin deficiency

Our center also provides access to clinical trials and observational studies to improve our knowledge of lung disease and facilitate access to novel therapies that could prove beneficial.



Ivan O. Rosas, M.D.
Professor and Chief
Section of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine


“I am interested in the development of novel diagnostic and therapeutic approaches to treat disabling lung diseases. Our clinical research focuses on early detection and treatment of pulmonary fibrosis.”

Dr. Rosas’ main area of research interest are the prevention, diagnosis and treatment of pulmonary fibrosis, a condition that affects genetically susceptible individuals and the elderly. Clinically his program has focused on defining populations at risk of developing pulmonary fibrosis, identifying disease biomarkers and the design and execution of clinical trials testing novel treatments for pulmonary fibrosis. In the laboratory, his research team employs cutting edge genomic technologies and translational models to determine how select molecular derangements contribute to the development and progression of parenchymal lung disease. The long-term goal of this translational research program is to better understand mechanisms that contribute to disease progression and to infor the development of novel diagnostic and therapeutic strategies for patients affected with fibrotic lung disease.



Baylor St. Luke’s Medical Center
6620 Main St. Suite 1475
Houston, TX
(832) 355-2285

Pulmonary Hypertension/CTEPH



The Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Program at Baylor St. Luke's Medical Center offers comprehensive, multidisciplinary care for patients with surgically and medically treatable CTEPH. As part of the broader Pulmonary Hypertension Program, we are one of the few centers equipped to evaluate and manage patients across the full therapeutic spectrum, including pulmonary thromboendarterectomy and balloon pulmonary angioplasty. Our growing program is anchored by a dedicated team spanning pulmonology, cardiology, interventional cardiology, cardiothoracic surgery, radiology, cardiac anesthesia, critical care medicine and hematology. We maintain structured case conferences to evaluate candidacy for intervention or transplant, ensuring individualized care aligned with best practices and long-term outcomes.




Ajith P. Nair, M.D.

Associate Professor, Medicine & Cardiology
Medical Director of Pulmonary Hypertension

"Baylor College of Medicine has a long legacy of pioneering pulmonary hypertension. We are enrolling patients into clinical trials and have state-of-the-art diagnostic and therapeutic technology. Our needs are still great if we want to be the best in the country, and our team is committed to going the distance for our community."


Meet Our Team Leaders

- Ajith Nair, M.D.
Pulmonary Hypertension Medical Director, Advanced Heart Failure, Cardiology
- Cyrus Vahdatpour, M.D., MSc
Pulmonary Hypertension/Transplant specialist, Pulmonary and Critical Care
- Hao-Min Pan, M.D., MSCE
Pulmonary Hypertension/Transplant specialist, Pulmonary and Critical Care
- Prangthip Charoenpong, M.D., MPH
Pulmonary Hypertension/Transplant specialist, Pulmonary and Critical Care



832-355-9125 or 832-355-9008 Office
832-355-3499 Fax
6620 Main St.
Houston Texas 77030
Ste. 1475

Lung Transplant Program



Gabriel Loor, M.D.
Professor of Surgery
Baylor College of Medicine

Surgical Director, Lung Transplant Program
Baylor St. Luke's Medical Center

Dr. Gabriel Loor, along with his collaborators Yaxin Wang, Ph.D., and Chris Chan, Ph.D., led Organvive to win the prestigious Shark Tank competition in March 2025, securing seed funding and comprehensive branding support to advance their innovative lung repair platform, OrganVive.. This ex vivo technology uses cold perfusion with blood and nutrients combined with natural-like ventilation to preserve and repair donor lungs for up to 48 hours—twice the duration of existing methods—while enabling targeted therapeutic delivery to rescue damaged lungs and expand the donor pool.



Nirmal Sharma, M.D.
Medical Director, Lung Transplant Center
Baylor St. Luke's Medical Center

"I am excited to join the Baylor College of Medicine team and lead the lung transplant program. The research and collaboration happening within the Lung Institute is known across the nation and is one of the key programs that recruited me to come back to Houston."

lungtransplant@stlukeshealth.org | (832) 355-9125

The Lung Transplant Program at Baylor St. Luke's Medical Center is a national leader in advanced lung disease and offers a variety of options for patients in need of a lung transplant.

The program is designated as a transplant center of excellence by Optum/United Healthcare and members of the team are pioneers of various innovations including the use of portable ex vivo lung perfusion for transportation and evaluation of donor organs. >100 lung transplants (#6 in the nation by volume)

- Single and double lung transplantation
- Multi organ transplants
- Ex vivo lung perfusion
- Transplantation in patients with extended risk, such as coronary artery disease
- Anti-rejection strategies



Erik Eddie Suarez, M.D.
Division of Cardiothoracic Transplantation
and Circulatory Support
Baylor College of Medicine


Director of Cardiothoracic Transplantation
Baylor St. Luke's Medical Center

"As someone who trained at the Texas Heart Institute, I have always known the value of bringing like-minded practitioners together to build strong clinical programs. Baylor College of Medicine Lung Institute represents one of the largest consortiums of lung-based care in the Nation. I cannot wait to be a part of it."



Alexis Edward Shafii, M.D.
Professor of Surgery
Jimmy and Roberta Howell Professor in Cardiovascular Surgery
Baylor College of Medicine

Surgical Director, Heart Transplantation
Director, Cardiovascular Critical Care Unit
Baylor St. Luke's Medical Center



Ramiro Fernandez II, M.D.
Assistant Professor of Surgery
Baylor College of Medicine



Determined patient
alive and grateful
thanks to Baylor
doctors





Research and Education Spotlight

Emma Hills, T32 recipient, conducting bioinformatics-driven lung transplant research with Rupa Kanchi and Christian Coarfa. Ethan Woods, training in biomedical informatics and data science at Rice University, focusing on predictors of chronic lung allograft dysfunction. Expansion of research operations with new coordinator Javier Arteaga.

Team Growth

Recruitment of Dr. Brittany Duong, lung transplant pulmonologist. Continued expansion of multidisciplinary collaboration across Baylor College of Medicine and Texas Heart Institute.


Global Impact

Participation in international lung transplant conference in India. Surgical training initiatives in Mexico City and Monterrey.


Selected Recent Publications

- Targeting the PGP-protease feed-forward loop to attenuate primary graft dysfunction after lung transplantation (*Frontiers in Immunology*, 2026)
- Spatial transcriptomics reveals coordinated epithelial-endothelial signaling in chronic lung allograft dysfunction (*Journal of Heart and Lung Transplantation*, 2026)
- Long-term outcomes of the international EXPAND trial of OCS lung preservation (*EClinicalMedicine*, 2025)
- Prospective randomized trial of VA-ECMO vs off-pump lung transplantation (*JTCVS*, 2026)
- Outcomes of central vs peripheral cannulation for intraoperative ECMO (*JHLT*, 2026)


Lung Transplant Case Volume



Advanced Lung Disease Clinic Volume



Lung Transplant Clinic Volume



*Projected

Center for Dysphagia and Swallowing Disorders

Aspiration, Dysphagia, Swallowing and Reflux


The Center for Dysphagia and Swallowing Disorders is an unparalleled collaboration between three unique specialties with dedicated interests in dysphagia. With a team of otolaryngologists, thoracic surgeons, gastroenterologists, radiologists, speech therapists and nutritionists, we evaluate and treat patients who have difficulty swallowing food or liquids. A commitment to research, advancing medical education and measurement of outcomes allows us to bring best-practice and state-of-the-art technologies to our patients.

The center strives to establish a diagnosis quickly and we work carefully with each patient to establish an individualized treatment plan.

Baylor Medicine | (713)798-8376 or (713)798-LUNG

- Botulinum toxin (Botox) injection
- Cricopharyngeal myotomy (endoscopic/open)
- Laparoscopic heller myotomy
- Laparoscopic hiatal hernia repair and Nissen fundoplication
- Laparoscopic paraesophageal hernia repair
- LINX procedure for GERD
- Speech and swallowing therapy
- Vocal injection/medialization
- Zenker’s diverticulostomy (endoscopic/open)
- Neurology consultation
- Psychiatry consultation
- Feeding tube placement
- Nutrition consultation
- Esophageal dilation
- Esophageal stent placement
- Photodynamic therapy
- Esophagectomy
- Minimally invasive esophagectomy
- Radiofrequency ablation of Barrett’s esophagus
- Peroral endoscopic myotomy (POEM)
- Pharyngeal dysfunction
- Aspiration
- Cricopharyngeal bar
- Cricopharyngeal dysfunction
- Vocal paralysis
- Esophageal dysmotility
- Achalasia
- Dermatomyositis
- Esophagitis
- Esophagogastric junction (EGJ) outflow obstruction
- Hypercontractile esophagus (jackhammer esophagus)
- Ineffective esophageal motility
- Scleroderma
- Reflux
- Gastroesophageal reflux disease
- Hiatal hernias
- Laryngoesophageal reflux
- Paraesophageal hernias
- Barrett’s esophagus
- Esophageal cancer
- Esophageal diverticuli
- Esophageal strictures
- Zenker’s diverticuli

Center for Airway, Voice and Swallowing Upper Airway & Tracheal Disease



Julina Ongkasuwan, M.D.
Professor and Chief, Laryngology
Otolaryngology - Head & Neck Surgery



“I am interested in how we produce voice and different treatment approaches for voice problems. I specialize in perceptual evaluations of voice problems, examination of patients with voice problems, including stroboscopic examination of the voice box.”

The Laryngology and Speech Pathology team at Baylor Medicine is dedicated to the care of patients with voice, airway and swallowing disorders. We employ advanced medical, surgical and behavioral approaches to diagnose and treat a wide range of conditions, including dysphagia (difficulty swallowing), voice disorders and airway obstruction resulting from laryngeal, subglottic or tracheal stenosis. Our team works in close multidisciplinary collaboration with experts in pulmonology, thoracic surgery, endocrine surgery, gastroenterology, neurology and oncology to ensure comprehensive, patient-centered care.

Baylor Medicine | 1977 Butler Boulevard | 713-798-5900

- Voice problems
 - Hoarseness
 - Dysphagia
 - Muscle tension dysphonia
 - Glottic stenosis & subglottic stenosis
 - Laryngopharyngeal reflux
 - Muscle tension dysphonia
 - Spasmodic dysphonia
 - Paradoxical vocal fold movement
 - Recurrent laryngitis
 - In-office vocal fold augmentation and therapeutic injections
 - Recurrent respiratory papillomatosis
 - Chronic cough
 - Early-stage laryngeal cancer
 - Vocal cord dysfunction
 - Vocal misuse and overuse
 - Vocal fold/cord paralysis, nodules, polyps and other benign lesions
 - Reinke’s edema
 - Tracheal stenosis
 - Tracheostomy management
 - Zenker’s diverticulum
 - Age-related vocal fold atrophy
- In addition to surgical and medical treatment, patients with airway, voice and swallowing conditions are often referred to a speech-language pathologist, who can provide additional evaluation and treatment options.
- Voice and swallow therapy
 - Professional voice care/singing voice rehabilitation
 - Head and neck cancer rehabilitation
 - Modified barium swallow study and flexible endoscopic evaluation of swallowing
 - Lee Silverman Voice Therapy (LSVT)

Congenital Tracheal & Lung Disease

Pediatric Lung Transplant



Jeffrey S. Heinle, M.D.
Professor and Chief
Division of Congenital Heart Surgery

Surgical Director, Lung Transplant Program
Texas Children's Hospital

"I focus on delivering children born with congenital lung disease the best possible future with the latest advances in technology."

The Texas Children's Hospital (Texas Children's) Lung Transplant Program ranks among the largest pediatric transplant programs globally and leads nationwide in performing pediatric lung transplants. In fact, over the past five years, under the leadership of Tina Melicoff, M.D., medical director of Texas Children's Lung Transplant Program, we have executed more than a quarter of all pediatric lung transplants in the United States.

Our nationally ranked specialist team has the experience and expertise to handle the most complex and rare cases. Skilled cardiothoracic surgeons, trained specifically in lung transplants, offer detailed surgical consultation. Teams include pulmonologists, nurse coordinators, dietitians, pharmacists, social workers, child life specialists, psychologist, physical and occupational therapists. Each of these disciplines provides comprehensive education in their area of expertise to facilitate a successful transplant.

Texas Children's is a globally recognized leader in extracorporeal membrane oxygenation (ECMO) care. ECMO provides life-prolonging care to critically ill patients until a suitable lung donor becomes available. Our extensive experience in ECMO as a bridge to transplant allows us to offer a lifeline to the most critical patients who might otherwise be ineligible for transplantation.

- Fetal lung problems
- Lung transplant
- Tracheal surgery
- Vascular slings and rings
- Tracheobronchoplasty
- Pleural disease
- CCAM (congenital cystic adenomatous malformation)



Ernestina Melicoff-Portillo M.D.
Assistant Professor of Pediatrics
Division of Pediatric Pulmonology
Baylor College of Medicine

Medical Director, Lung Transplant Program
Texas Children's Hospital

"The team at Texas Children's Hospital delivers multidisciplinary expert care at every step along a patient's journey from early lung disease to advanced lung transplantation. As one of the leading pediatric lung transplant programs in the country, we focus on delivering integrated and quality-focused care."

Leading the Nation and the World

Texas Children's Hospital stands at the forefront of pediatric respiratory and circulatory care, notably through its Lung Transplant Program—one of the largest in the world—and its nationally recognized Pulmonary Hypertension Program. The lung transplant team delivers multidisciplinary expert care at every step along a patient's journey from early lung disease to advanced lung transplantation. As one of the leading pediatric programs in the country, we focus on delivering comprehensive and family-centered care.

Program Highlights

- Largest pediatric lung transplant program in the country
- Supports a pediatric population from infancy through young adulthood
- 20 years of extensive experience in pediatric lung transplantation
- Dedicated specialty teams collaborate to ensure comprehensive care
- Extracorporeal membrane oxygenation as a bridge to lung transplantation

Texas Children's Hospital
(832) 826-7100



Endometriosis Center

Pleural Endometriosis



Xiaoming Guan, M.D., Ph.D.
Professor and Chief
Division of Minimally Invasive Gynecologic Surgery
Obstetrics and Gynecology

Baylor Medicine endometriosis specialists have long been recognized for their expertise in diagnosing and treating endometriosis, providing much-needed relief for women searching for help.

Treatment is provided by board-certified, fellowship-trained minimally invasive gynecologic surgeons highly skilled in excision surgery. These experienced surgeons work in concert with a diverse team of Baylor Medicine specialties to treat all aspects of a woman's health affected by endometriosis.


Texas Children's Pavilion for Women | (832)-826-7500

Dr. Xiaoming Guan, M.D., Ph.D., is a nationally recognized leader in minimally invasive gynecologic surgery and a pioneer in advanced robotic-assisted techniques. He is a leading expert in endometriosis surgery, with a clinical focus on advanced robotic and minimally invasive approaches to complex cases. He is the advisor of Endometriosis Foundation of Houston(EFHou) and the T shirt with " Guan Gang" was honored in this foundation.

Dr. Guan has performed over 1,800 robotic surgeries and more than 1,500 endometriosis excision procedures, including some of the most complex cases involving the bowel, ureter, pelvic nerves, diaphragm, pleura and other extrapelvic sites.

A trailblazer in surgical innovation, Dr. Guan is the highest-volume surgeon for uniportal robotic surgery, encompassing both transumbilical and transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES). He is also the first MIGS surgeon to perform all stages of pelvic endometriosis surgery exclusively through robotic vNOTES.

Since 2021, Dr. Guan has expanded the endometriosis program by recruiting three additional MIGS surgeons—Dr. Joseph Nassif, Dr. Tamisa Koythong and Dr. Brooke Thigpen—who also specialize in complex endometriosis care. Through their MIGS fellowship program, the team has trained 12 skilled endometriosis surgeons, now practicing across the United States and contributing to the advancement of gynecologic surgery through clinical excellence, research and mentorship.



Magnetic Resonance Imaging demonstrates blood in the chest of a patient suffering from pleural endometriosis.

**THE
STITCH**
thestitchblog.com

Endometriosis and the
lesser-known thoracic
endometriosis syndrome




Chest Wall Resection and Reconstruction



Sebastian Winocour, M.D., MBA
Professor and Associate Chief
Division of Plastic Surgery
Baylor College of Medicine
Section Chief of Plastic Surgery
Baylor St. Luke's Medical Center



Marco Maricevich, M.D.
Associate Professor
Chief, Plastic Surgery
Ben Taub Hospital



Lyahn Hwang, M.D.
Assistant Professor of Surgery
Division of Plastic Surgery
Baylor College of Medicine

The Chest Wall Resection and Reconstruction Clinic focuses on tumors of the chest wall and deformity of the chest wall from trauma or congenital defects. Our teams specialize in analyzing chest wall images from CT scans or MRI to diagnose characteristics that can lessen the need for biopsy. When a biopsy is warranted, we work closely with oncology colleagues and the multidisciplinary tumor board to ensure patients are appropriately treated for chest wall tumors.

- Chest wall tumors
- Pectus excavatum
- Pectus carinatum
- Chest wall trauma
- Chest wall hernias

Baylor Medicine | (713)798-8376 or (713)798-LUNG



Research:

Our teams are currently working with industry partners to create customized 3D printed chest wall reconstructions with material uniquely suited to function like human ribs. Our collective experience and systematic approach made innovation in this area a key area of innovation interest. Research protocols and collaboration with the FDA enable our programs to measure results and improve outcomes.

Family Medicine



Baylor Medicine family physicians provide primary care to individuals and the entire family—from adolescents to older adults. The clinics offer lung cancer screening and smoking cessation services to underserved and high-risk areas in Texas, including Polk and San Jacinto Counties. Building on the Harris County Healthy Lung Cancer Screening Program, the new Lung Cancer Screening and Tobacco Control (LCTC) Network will train 250 primary care providers, offer 450 free screenings and provide smoking cessation treatment to 3,000 patients. The program aims to reach 20,000 community members and reduce lung cancer mortality by 20%.

Baylor Medicine | 713-798-7700

Extended hours, next-day appointments, telehealth visits, virtual Saturday visits and three convenient locations make it quicker and easier to get the care patients need. Our physicians speak several languages, providing options to Houston's diverse community.

Lung Cancer Screening locations

Harris Health Ben Taub Hospital (713) 526-4243	Baylor St Luke's Medical Center (832) 354-1000
Michael E. DeBakey VA Medical Center (800) 698-2411	Dan L Duncan Comprehensive Cancer Center <i>One of only three NCI Designated Cancer Centers in Texas.</i> (832) 957-6500
Baylor College of Medicine Concierge Healthcare Program (713)798-7877 or fax (713)798-1830	

The Duncan Cancer Center is designated by the National Cancer Institute.

Fungal Disease and Sinusitis Clinics



David B. Corry, M.D.
Professor of Medicine-Immunology,
Allergy and Rheumatology
Fulbright Endowed Chair in Pathology
Baylor College of Medicine

"I have spent my career studying the relationships between allergic fungal sinusitis and allergic lung disease to determine the best ways to detect, treat and monitor allergic airway inflammation."


(713)798-8740



Dr. Corry's laboratory focuses on unraveling the molecular pathways that drive lung and sinus inflammation through the study of humans and experimental models. Key discoveries include defining the fungal infectious basis of asthma and sinusitis and the roles that the inflammatory protein interleukin 13, platelets, and clotting factors play in driving fungus-dependent inflammation.

The team further studies how genetic mutations drive susceptibility to fungal airway infections.

Working with other Baylor allergists, Dr. Corry has developed protocols for the safe use of currently available antifungals and anti-inflammatory agents in fungal asthma and sinusitis. The laboratory is further developing novel anti-inflammatory and antifungal drugs for use in these conditions.




Evan Li, M.D.
Assistant Professor of Medicine
Immunology, Allergy & Rheumatology
Baylor College of Medicine

"My research in fungal sinusitis and mucoobstructive airway disease focuses on identifying pathways and signaling mechanisms which contribute to airway obstruction. My patients are often pleased to see how the work I am doing in the lab translates into clinical practice. The knowledge we acquire helps us to better understand how to manage and monitor their disease. The Lung Institute is a perfect arena for building bridges with other researchers, getting support, disseminating what we have learned and building stronger programs."

(713)798-2344

Allergic diseases are often seen as misguided immune responses that cause more harm than benefit. However, new research led by an international team at Baylor College of Medicine reveals that certain allergic reactions play a vital role in protecting against highly invasive and potentially deadly infections, such as those caused by yeast.



Baylor College of Medicine - McNair Campus
7200 Cambridge Street
Houston, TX 77030
(713) 798-1555

Interventional Pulmonology



Javeryah Safi, M.D.

Assistant Professor
Interventional Pulmonary
Section of Pulmonary and Critical Care Medicine

"I strive to deliver the least invasive and most personalized diagnostic and therapeutic interventions. As a pulmonologist, seek to get my patients staged and treated in the safest and most timely manner. Our teams strive to deliver an exceptional experience."

Baylor Medicine | 7200 Cambridge St., Suite 6A | (713) 798-2678



Babith Mankidy, M.D.

Assistant Professor
Interventional Pulmonary
Section of Pulmonary and Critical Care Medicine

"I provide interventional pulmonary input to the lung transplant service at Baylor St. Luke's Medical Center and my dual experience in transplant medicine and interventional pulmonary gives me added ability to tackle complex post transplant airway concerns."

The Interventional Pulmonology Program is one of the largest lung centers in Texas that provides interventional pulmonology. As part of our comprehensive lung program, our board-certified interventional pulmonologists perform advanced diagnostic bronchoscopy, pleural procedures and therapeutic bronchoscopy. We offer consultation services for both malignant and benign disorders of the lung and the airways and a multidisciplinary approach to evaluation and management.

- Lung cancer
- Lung nodules
- Airway obstruction due to cancer
- Hemoptysis
- Tracheal stenosis
- Pneumothorax
- Pleural effusions
- Emphysema and COPD for valve placement
- Prolonged air leaks after surgery
- Pulmonary alveolar proteinosis



IP Procedures and Technology:

Advanced Diagnostic Bronchoscopy


- Endobronchial Ultrasound (EBUS)-guided transbronchial needle aspiration
- Electromagnetic navigational bronchoscopy
- Robotic bronchoscopy and biopsy
- Radial endobronchial ultrasound
- Transbronchial cryobiopsy

Pleural Procedures:

- Pleural ultrasound
- Thoracentesis
- Tunneled indwelling pleural catheter placement
- Pleurodesis


Therapeutic Bronchoscopy

- Rigid bronchoscopy
- Laser and Argon plasma coagulation
- Electrocautery/electrosurgery
- Microdebrider
- Endobronchial cryotherapy
- Airway stent placement
- Foreign body removal
- Balloon dilation
- Endobronchial valve placement for persistent air leaks
- Bronchoscopic lung volume reduction for COPD
- Bronchial thermoplasty for asthma
- Tracheostomy management
- Whole lung lavage
- Fiducial placement for radiation therapy



Lung Cancer Screening

Michael E. DeBakey VA Medical Center



Farrah Kheradmand, M.D.
 Professor of Medicine,
 Director, Lung Cancer Screening Program
 Nancy Chang, Ph.D. Endowed Professorship
 Biology of Inflammation Center
 Baylor College of Medicine
 Co-Lead for Tumor Biology Program
 Dan L Duncan Comprehensive Cancer Center
 Co-Director of the Lung Precision Oncology Program
 Michael E. DeBakey VA Medical Center



"I am interested in detecting lung cancer in the earliest stages of disease when we still have a chance for cure. My research is related to smoking-related lung diseases and the molecular mechanisms of lung cancer development."




Lorraine D. Cornwell, M.D.
 Associate Professor of Surgery
 Baylor College of Medicine
 Section Head of General Thoracic Surgery
 Michael E. DeBakey VA Medical Center

"As the section head for general thoracic surgery and co-investigator for the lung cancer screening program, I am dedicated to detecting lung cancer at the earliest stage. When lung cancer is detected early, surgeons can often offer curative surgery."

Lung Precision Oncology Program (LPOP) hub at the Michael E. DeBakey VA Medical Center (MEDVAMC) was funded in 2021 with the mission to improve the lives of veterans with cancer through early detection and precision medicine. The MEDVAMC LPOP mission closely follows the VA vision in providing the best-in-class lung cancer care through an integrated oncology systems of excellence using the Hub and Spokes model. Drs. Kheradmand and Cornwell have successfully implemented multiple goals as evidenced by their compliance with performance metrics including initiating lung cancer clinical trials, lung cancer screening programs (LCSP), expanding LCSP Spoke sites, and performing molecular testing when appropriate in new lung cancer cases. Together, these new initiatives and expansions have improved Veteran access to care and precision oncology trials. The infrastructure support from LPOP, extramural, and private fundings, the MEDVAMC LPOP has expand the lung cancer clinical and research programs through the following Aims:

- Clinical program in early detection of lung cancer
- Precision oncology lung cancer clinical trials
- Education and training in lung cancer


Cumulative Total of Patients Offered and Accepting Lung Cancer Screening, and Eligible at Time of Assessment



The Michael E DeBakey Veterans Affairs Medical Center (MEDVAMC) Milestones: Cumulative total of veterans offered and accepted lung cancer screening, who were eligible at time of assessment per quarter. Data acquired from the Lung Precision Oncology Program (LPOP) dashboard demonstrate a steady growth of the Lung Cancer Screening Program (LCSP) that ensured enrollment of eligible veterans engaged in the screening program at MEDVAMC. B) Since the second quarter in FY 2022, the program has identified over 7,200 veterans who qualify for lung cancer screening. Over 6,200 have been offered low-dose CT screening scans and over 3,800 have completed scans.


LPOP

Implementation, Expansion, and Interim Outcome of Systemic Lung Cancer Screening Program Supported by the Lung Precision Oncology Program (LPOP) at the MEDVAMC.



Michael E. DeBakey VA Medical Center
 2002 Holcombe Boulevard
 Houston, TX

Minimally Invasive Segmentectomy



Pulmonary Segmentectomy is a type of surgery used to treat lung cancer by sparing the portions of the lung that are not involved. This can translate into more lung left behind to preserve function and breathing. Patients with multiple lung cancers often benefit most from this technique. Surgeons at Baylor specialize in minimally invasive pulmonary segmentectomy.




Read the blog:
What is pulmonary
segmentectomy?



Laryngeal and Tracheal Tumor Program



N. Eddie Liou, M.D.
Associate Professor
Head and Neck Surgery
Bobby R. Alford Department
of Otolaryngology



RayWang, M.D.
Assistant Professor
Head and Neck Surgery
Bobby R. Alford Department
of Otolaryngology

The laryngeal and tracheal tumor program focuses on the complex removal of benign and malignant tumors in the upper most aspect of the airway. Goal directed care is centered around optimization of speech and swallow outcomes in the face of complete tumor removal. Surgeries performed may range from endoscopic laryngeal sparing procedures to total laryngectomy or tracheal resection. Longitudinal care is also provided to ensure long term voice rehabilitation.

Our multidisciplinary approach to tumor and cancer care incorporates the expertise of a team which includes thoracic surgeons, radiation oncologists, medical oncologists, neuroradiologists, head and neck pathologists and speech and language pathologists.

- Primary tumors (benign and malignant) of the upper trachea and larynx
- Advanced thyroid carcinoma with laryngeal and upper tracheal involvement
- Upper tracheal and subglottic stenosis
- Radionecrosis of the upper trachea and larynx
- Complications of tracheostomy dependence

Jamail Specialty Care Center
1977 Butler Blvd.
Houston, TX 77030
(713) 798-5900

Medical Mass Spectrometry Technologies




Livia S. Eberlin, Ph.D.

Professor and Vice Chair for Research
Translational Research and Innovations Endowed Chair
Director, Translational and Innovations Research
Co-Director, INSTINCT
Michael E. DeBakey Department of Surgery

“We are extremely passionate about developing new molecular technologies that can advance and expedite care for patients with lung cancer and other diseases. Our MasSpec Pen device, for example, has the potential to both accelerate diagnosis of lesions in bronchoscopies as well as assessment of lung cancer surgical margins to improve precision in surgical treatment.”

One of our exciting inventions, MasSpec Pen technology, has been featured on the television series “Grey’s Anatomy” and is currently being tested by surgeons in the Texas Medical Center. Our lab is funded by the NIH, CPRIT and other medical and research foundations.

Our laboratory’s expertise is in the development and application of direct mass spectrometry technologies for tissue analysis and disease detection. Research projects are focused on the identification of metabolic markers of cancer and other diseases, as well as in the development of mass spectrometry based medical devices for surgical use. We use a combination of chemistry, mass spectrometry, statistical analysis, machine learning and device prototyping techniques to solve complex problems in biomedical research and develop new technologies to improve patient care.



Lung Genomics and Genetics



Richard A Gibbs, Ph.D.
Wofford Cain Chair and Professor
Molecular & Human Genetics
Director, Human Genome Sequencing Center



“The visionary quest was launched to sequence the human genome so that we would have this foundation to do all of it—whatever ‘it’ turned out to be. It was a big breakthrough upon completion, and the question immediately became, ‘How do we push the genome into medicine?’ Because impacting health is really what it’s all about.”

The HGSC Clinical Laboratory (HGSC-CL) is the CAP/CLIA certified molecular diagnostic laboratory operating within the Human Genome Sequencing Center at Baylor College of Medicine.

With a commitment to improving health care through genomic testing, HGSC-CL offers clinical testing services in support of large-scale clinical sequencing efforts.

HGSC | agibbs@bcm.edu | (713)798-6539

Baylor
College of
Medicine

DEPARTMENT OF
MOLECULAR & HUMAN
GENETICS

Medical Oncology

Dan L Duncan Comprehensive Cancer Center



Meera Patel, M.D., MHS
Assistant Professor
Section of Medical Oncology
Department of Medicine
Director, Thoracic Oncology Program



“Directing our thoracic cancer program is a highlight for my career. I enjoy working alongside my surgical, radiation and pathology colleagues to find the best customized treatment plan for my patients. We find exceptional ways to go above and beyond to deliver unexpected outcomes whenever possible.”

The Dan L Duncan Comprehensive Cancer Center at Baylor St. Luke’s Medical Center brings innovative treatments from lab to bedside faster than ever before to help stop cancer in its tracks.

Set apart from other centers by its Comprehensive Cancer Center designation by the National Cancer Institute (NCI), the center provides exceptional care to patients from all over the world. As one of only three NCI-designated Comprehensive Cancer Centers in Texas, the Duncan Cancer Center is one of the best in the country and contributes vital advances to cancer research through national funding. Specialized health care providers, including oncologists and radiologists are dedicated to understanding, preventing and treating various types of cancer.

- Breast Cancer
- Colorectal Cancer
- Gastrointestinal Cancer
- Genitourinary Cancers
- Gynecologic Cancers
- Head and Neck Cancers
- Leukemia and Lymphoma
- Liver Cancer
- Lung Cancer
- Mesothelioma
- Melanoma and Skin Cancer
- Neuroendocrine Tumors
- Pancreatic Cancer
- Prostate Cancer



Recognized for scientific and clinical excellence, the Duncan Cancer Center is home to exceptional discoveries and the development of more effective approaches to cancer prevention, diagnosis and treatment. In addition, the center performs outstanding cancer epidemiology and prevention research and sponsors innovative clinical trials of new preventive and treatment strategies.

Duncan Cancer Center | (832) 957-6500

Mesothelioma Treatment Center



Shawn Groth, M.D.
Professor and Chief, David J. Sugarbaker Division of Thoracic Surgery
David J. Sugarbaker Professor of Thoracic Surgery
Baylor College of Medicine

Director, Esophageal Surgical Services
Baylor St. Luke's Medical Center



The Mesothelioma Treatment Center is recognized worldwide as a leading-edge center for the diagnosis, treatment and research of malignant mesothelioma. Our physicians and staff use leading-edge medical techniques, including genetic and genomic approaches, combined with essential support and therapy to treat the whole person. To overcome the challenges of treating mesothelioma, we are actively committed to conducting clinical trials with new treatments, pharmaceuticals and procedures.



Baylor Medicine | 7200 Cambridge St. | (713) 798-6376

Bronchiectasis and Non-Tuberculous Mycobacterial Disease (NTM) Program



Sunjay Devarajan, M.D.
Assistant Professor
Section of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine

“The Baylor NTM program offers patients a unique opportunity to build real-time treatment plans in a single visit rather than bounce around the offices of multiple specialists seeking answers. It efficiently fills a community and public health need.”



Baylor Medicine | ntmclinic@bcm.edu | (713) 798-2400



Ahmed Hamdi, M.D.
Assistant Professor
Section of Infectious Diseases
Department of Medicine

“I particularly enjoy working across specialties and alongside Dr. Devarajan to develop care plans for patients with complex pulmonary infections. The multidisciplinary nature of our practice helps patients find answers quicker and in a manner that is more closely aligned between providers.”


The Baylor Medicine Non-Tuberculous Mycobacterial Disease (NTM) Program consists of a multi-disciplinary team of infectious disease specialists, pulmonologists, microbiologists and respiratory therapists working together to design the most effective treatment plan for our patients. This approach offers a unique opportunity to build real-time treatment strategies in a single visit, reducing wait times and improves efficiency.

Treatment for NTM infections is complex and usually involves a combination of antibiotics taken over a long period of time with frequent monitoring of sputum cultures, chest imaging and pulmonary function tests. Additional treatments may include pulmonary rehabilitation for symptom management and even surgery to remove infected tissue, particularly if the infection is localized to a specific lung area.


Palliative Care



Charu Agrawal, M.D.
Assistant Professor
Medical Director,
Palliative Medicine
Baylor St. Luke's Medical Center
Dan L Duncan Comprehensive
Cancer Center



Paige Farinholt, M.D.
Assistant Professor
Palliative Medicine
Dan L Duncan Comprehensive
Cancer Center




Kaoswi Karina Shih, M.D.
Assistant Professor
Palliative Medicine
Dan L Duncan Comprehensive
Cancer Center

Our supportive care team includes specially-trained physicians, nurses and social workers who work together with a patient's other doctors to provide an extra layer of support. Unique to Dan L Duncan Comprehensive Cancer Center, the team is embedded within medical oncology so that patients can see their oncologists and palliative care on the same day and in the same place.

- Symptom management
- Support through communication and coordination of care with oncologist
- Advance care planning


Post-COVID Care Clinic



Fidaa Shaib M.D.
Associate Professor
Section of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
Chief Medical Officer, Baylor Medicine

“Our community of patients who continue to suffer from COVID-19 will need ongoing care. The Post-COVID clinic is created to meet those needs and help patients recover to get back to their best condition possible.”

At the Post-COVID Care Clinic, a multidisciplinary team provides care in a compassionate and holistic approach to those inflicted with residual symptoms and long-term health issues, most of which are not well defined nor understood. Also known as “long-haulers,” patients with long-term effects from COVID-19 often have respiratory symptoms such as cough or chest pain. However, patients recovering from COVID-19 experience many symptoms related to multiple organ systems. Our goal is to evaluate and provide state-of-the-art care to patients recovering from COVID-19, incorporating telehealth, when appropriate.



Baylor St. Luke's Medical Center
7200 Cambridge St.
Houston, TX 77030
(713)798-5864

Duncan Cancer Center | (832) 957-6500

Radiation Oncology



Zaid Siddiqui, M.D.
Assistant Professor
Radiation Oncology

“At Baylor, our multidisciplinary team works together to customize a plan of care to fit every patient’s unique physical and emotional needs and to respect their values. When designing radiation plans, no two patients are the same—working with the Baylor team allows me to reduce the burden of treatment, provide optimum support to patients and their families, and provide timely, high-quality care.”

As a high-volume center, Baylor Radiation Oncology routinely performs procedures that may be done only occasionally at other locations. Studies have shown that centers performing higher volumes of procedures have better patient outcomes.

Types of Radiation Therapy:

3D Conformal Treatment Planning and Delivery: Three-dimensional conformal radiation therapy (3D-CRT) is an emerging technology in radiation therapy that involves multimodality imaging techniques, accurate radiation dose calculation methods, computer optimized treatment planning and computer- controlled treatment delivery.

Intensity Modulated Radiation Therapy: This advanced type of radiotherapy uses a computer-controlled device called a linear accelerator to deliver precise doses of radiation to tumors or specific areas within the tumors.

Image-Guided Radiation Therapy: IGRT uses frequent imaging during a course of radiation therapy to improve the precision and accuracy of the delivery the radiation treatment.

Stereotactic Radiosurgery: Despite its name, radiosurgery is a treatment, not a surgical procedure. This non-invasive procedure involves highly precise, large doses of radiation to ablate tumors in the lung while minimizing damage to healthy tissue.

Radioimmunotherapy: Radioimmunotherapy is mainly used to treat lymphoma and lymphocytic leukemia. It combines a radioactive substance with a monoclonal antibody that’s injected (infused) in your body. The monoclonal antibody targets, and sometimes reacts with, proteins on cancer cells called antigens. The radioactive molecule destroys the cells.



Baylor St. Luke’s Medical Center
7200 Cambridge St.
Houston, TX 77030
(832) 957-6500

SMOKING CESSATION

Schedule Your Consultation Today!

7200 Cambridge St.
Houston, TX 77030
713-798-LUNG

Find out more

E-Cigarettes and Vaping

While e-cigarettes are often marketed as a safer alternative to traditional smoking, they still come with several health risks:

- Vaping can lead to dependency, especially in adolescents, whose brains are still developing
- E-cigarette vapor can contain harmful substances (formaldehydes/acetaldehydes, heavy metals like lead, nickel and tin)
- Some might contain unknown or mislabeled ingredients
- E-cigarettes can pose a fire and explosion hazard, primarily due to their lithium-ion batteries.

Take control of your health—your future self will thank you!

Baylor Medicine

Schedule Your Consultation Today!

7200 Cambridge St.
Houston, TX 77030
713-798-LUNG

Find out more

Smoking Cessation

Quit Smoking, Breathe Easy!

Ready to Quit? We are here to help!
Join our Smoking Cessation Program for expert guidance, support and resources to help you succeed. Smoking is the leading cause of lung disease and complications after surgery. Quitting now can:

- Lower your risk of lung cancer and heart disease
- Boost lung function and improve overall health
- Keep your loved ones safe from harmful secondhand smoke
- Enhance surgical recovery and healing

Our Program Offers:

- Personalized Quit Plans – Strategies designed to support your unique journey
- Compassionate Counseling – Encouragement and guidance from our dedicated team
- Nicotine Replacement Options – Access to patches, gum and medications to ease the transition
- Healthy Coping Techniques – Practical ways to manage stress and cravings
- Continuous Support and Check-Ins – You’re never alone—We’ll be there with regular follow-ups, motivation and tools to help you stay on course.

Quitting smoking is a powerful step toward better health—no matter where you are on your journey, we’re here to support you every step of the way.


Baylor Medicine



During initial consultation, patients will receive information regarding the Tobacco Cessation Program and answers to any questions they might have. Treatment specialists will evaluate tobacco use and related factors that may trigger or influence tobacco usage. A detailed plan for treatment and quitting will be created. One to two week follow-up visits (eg, telemedicine encounters or in-person office visit) will be advised to offer support, monitor for adverse pharmacologic effects and emphasize adherence to medication.

Baylor Medicine | 7200 Cambridge Street | 713-798-6376


Systems Onco Immunology Laboratory (SOIL)



Hyun-Sung Lee, M.D., Ph.D.
Associate Professor of Surgery
Michael E. DeBakey Department of Surgery
David J. Sugarbaker Division of Thoracic Surgery
Director, Systems Onco-Immunology Lab
Baylor College of Medicine

The Systems Onco-Immunology Laboratory (SOIL) at Baylor College of Medicine, under the leadership of Hyun-Sung Lee, M.D., Ph.D., is a pivotal center for translational oncology research. This interdisciplinary hub unites surgeons, medical oncologists, immunologists, geneticists, proteogenomic experts and bioinformaticians in the pursuit of groundbreaking research in onco-immunology. SOIL's work extends beyond research, encompassing educational endeavors in systems onco-immunology and active engagement with the scientific community. Its core aspects are: Sophisticated Research Infrastructure, Onco-Immunologic Personalized Medicine, Integration with Clinical Practice, Leadership in Interdisciplinary Collaboration and Educational Excellence and Community Involvement. Through this structured and visionary approach, SOIL is set to make significant strides in onco-immunology within surgical oncology, combining innovative research, clinical application, educational leadership and community outreach.

Sleep Medicine and Snoring



Fidaa Shaib M.D.
Associate Professor
Section of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
Chief, Medical Officer, Baylor Medicine



Philip Mani Alapat, M.D.
Associate Professor
Section of Pulmonary, Critical Care & Sleep Medicine
Department of Medicine
Program Director, Pulmonary and Critical Care
Medicine Fellowship

The Baylor Medicine Sleep Clinic specializes in diagnosing and treating a wide range of sleep disorders. The clinic is led by Dr. Fidaa Shaib, who serves as the director of both the Sleep Medicine Clinic and the Sleep Center. Our team of experts provide thorough evaluations and personalized treatment plans for a wide range of sleep-related conditions.


We collaborate closely with Baylor Medicine ENT to offer advanced treatments like hypoglossal nerve stimulation (Inspire) for obstructive sleep apnea. Additionally, the center works with the neurology department to coordinate care for patients requiring home ventilation, both non-invasive and invasive.

- Sleep apnea
- Snoring
- Insomnia
- Narcolepsy
- Parasomnias
- Restless leg syndrome (RLS)
- Shift work disorder
- Non 24 sleep-wake disorder
- Excessive sleepiness



Baylor St. Luke's Medical Center
7200 Cambridge St.
Houston, TX 77030

(713) 798-LUNG (713) 798-3300



The Thoracic Surgery Clinic at Baylor Medicine’s Lung Institute specializes in the care and treatment of patients with benign and malignant disorders of the chest cavity. This includes lung cancer, esophageal cancer, thymoma, mesothelioma and all other malignancies involving the thorax.

Together with the outstanding support staff of nurses, nurse practitioners and physician-assistants, our surgeons attract patients from all over Texas, and from across the United States. An international program for patients from around the globe is available for those who need special help and assistance.

In addition to outstanding clinical care, our surgeons and staff are committed to the development of new treatments for thoracic disease through research and innovation. New technology drives their innovative techniques that lead to less pain after surgery and a speedier postoperative recovery.



Clarity of Purpose and focused attention are indeed the essence of excellence

Dr. David J. Sugarbaker was the founder of the Lung Institute and the Division of Thoracic Surgery within the Department of Surgery at Baylor College of Medicine. The surgeons he recruited to Houston continue to drive excellence in patient care. His legacy will continue to live on as the current members of the David J. Sugarbaker Division of Thoracic Surgery.



Read the blog:
Surviving cancer and
tracheoesophageal fistula:
Sandy Tovey’s journey



- Baylor Medicine | lungsched@bcm.edu | (713)798-6376
- Lung Cancer
 - Mesothelioma
 - Esophageal cancer
 - Thoracic outlet syndrome
 - Thymoma and mediastinal tumors

- Reflux and benign esophageal diseases
 - GERD
 - Slipping rib syndrome
 - Trachea disorders
 - Benign lung diseases

Robotic Thoracic Surgery




Our robotic thoracic surgery program is recognized as one of the top ten programs in the nation. Every thoracic surgeon in our division performs minimally invasive surgery and is certified and credentialed to perform robotic lung resections.

We specialize in robotic navigational bronchoscopy for minimally invasive lung biopsies, robotic esophagectomy for treatment of esophageal cancer as well as robotic lung resections. Our teams are trained to perform robotic tracheobronchoplasty to offer advanced solutions for tracheal reconstruction.

One of the main benefits of robotic thoracic surgery versus open surgery is that it is a less invasive procedure. This means that there are smaller incisions, less blood loss, and a shorter hospital stay. Patients who undergo robotic thoracic surgery also tend to experience less pain and scarring than those who have open surgery.



Baylor Medicine at McNair Campus
7200 Cambridge St.
Houston, TX 77030
(713) 798-LUNG



Baylor St. Luke's celebrates 300th robotic-assisted bronchoscopy

More than 300 Baylor St. Luke's Health patients have now benefited from a robotic-assisted bronchoscopy, a minimally invasive procedure allowing doctors easier access to the lungs to detect cancers.

Robotic-assisted bronchoscopies help doctors reach small, difficult-to-access nodules in the lung with improved accuracy and less risk compared to a traditional bronchoscopy. The advanced procedure, performed using the ION System, offers patients faster recovery times and earlier diagnoses.



Exceptional minds. Thoughtful care. Endless possibilities.

Collaboration fuels innovation. By partnering with Baylor College of Medicine, we bring tomorrow's treatments closer to every patient we serve.

Learn more at commonspirit.org/bslmc



**Baylor St. Luke's
Medical Center**



A member of CommonSpirit

Baylor
College of
Medicine

Single Port Robotic Surgery



Baylor College of Medicine Thoracic Surgeons and Baylor St. Luke's Medical Center teams have partnered together to offer patients single port robotic surgery. This novel new platform enables surgeons to deliver the same level of robotic technology but through a keyhole approach and often outside the ribs. By keeping ports away from the ribs, post-procedural pain may be less than traditional ports.



Partnering to Support Your High-Risk Patients

At Texas Children's Pavilion for Women, our Maternal Fetal Medicine (MFM) team is committed to providing exceptional care for high-risk pregnancies through comprehensive total care obstetric services, collaborative co-management, and expert consultations. Our team is here to support you and your patients every step of the way.

Benefits for Mother and Baby

- We are proud to be designated as a **Level IV maternal care center**, offering the highest level of care available for expectant mothers with complex medical needs.
- The **Placenta Accreta Spectrum (PAS) Center** provides specialized care from diagnosis with highly specialized imaging through delivery with a multidisciplinary medical and surgical team to ensure safest outcomes for your patients.
- The **Maternal Heart Program** is a unique collaboration between MFM and our adult congenital heart disease specialists who provide comprehensive care for patients with cardiac disease for preconception consultation and antepartum care.
- Our specialty programs for high-risk pregnancies include **Placenta Accreta Spectrum, Maternal Heart, Program for Multiples**, and integrated specialty consultations with **Rheumatology, Renal, Transfusion Medicine and Neurology**.
- Partnered with the nationally recognized **Texas Children's Fetal Center®** in providing excellence in fetal diagnostics and interventional therapies. This center provides families with access to world-class specialists and cutting-edge treatment options.
- Our dedicated **OB Intensive Care Unit (ICU)** is one of the few in the nation solely focused on obstetric critical care. Staffed 24/7 by a pulmonary critical care team and MFM and hospitalist specialists, it ensures rapid, expert response to emergencies with coordinated critical care.
- **Texas Children's Kangaroo Crew** offers specialized maternal transport services, ensuring that high-risk patients are safely transferred to the Pavilion for Women with expert care provided by our dedicated team throughout the journey.
- Immediate access to **Texas Children's Level IV Neonatal Intensive Care Unit (NICU)** ensures lifesaving interventions for newborns. **NICU couplet care** prioritizes keeping mothers and their babies who require NICU care together whenever possible.

Meet our Total Care MFM Team:



Manisha
Gandhi, MD

Maternal Fetal
Medicine



Hennie
Lombaard, MD

Maternal Fetal
Medicine



Christina Ackerman-
Banks, MD

Maternal Fetal
Medicine



Nevert Badreldin,
MD, MS

Maternal Fetal
Medicine



Kelli Diane
Barbour, MD

Maternal Fetal
Medicine



Sarah Detlefs,
MD, MS

Maternal Fetal
Medicine



Abida
Hasan, MD

Maternal Fetal
Medicine



Alexander
Saucedo, MD

Maternal Fetal
Medicine



Amir A.
Shamshirsaz, MD

Maternal Fetal
Medicine



Onur Turkoglu,
MD

Maternal Fetal
Medicine



To refer a patient

Complete the Maternal-Fetal Medicine referral form online at texaschildrens.org/refer

- Select **Pavilion for Women**
- Select the **Maternal-Fetal Medicine** department
- Select **Texas Medical Center**
- Choose the **Online Referral Form** and complete the form
- Select **Complete Transfer of Care** as the reason for consultation

If you believe the situation is **urgent** or would like to speak with someone about your patient, call **832-826-4MFM** and ask to speak with an **MFM nurse**. For hospital-to-hospital transfers and transports, call **832-824-5550**.

Texas Children's Pavilion for Women
Medical Center
6651 Main St., Suite F420
Houston, TX 77030
832-826-4MFM (4636)

@PavilionForWomen

/PavilionForWomen

© 2025 Texas Children's Hospital. All rights reserved. PFW-31589-25

Lung Institute Publications

January 2025 – January 2026

ALAPAT P

Faiz SA, Warner MT, Lazarus DR, Ong P, Proud KC, Dinh K, Sargsyan LA, Sanchez JF, Hoffman MI, Zaidan MF, Abdelghani R, Alapat P, Richards K, Bashour S, Meena N, Walter RJ, Islam E, Nishi SP, Vu CN, Kelly WF, Eapen GA. Delivering a Regional Procedural Bootcamp for Incoming Pulmonary and Critical Care Medicine Fellows. *Chest.* 2025 Dec;168(6):1433-1442. doi:10.1016/j.chest.2025.06.011. Epub 2025 Jun 17. PMID: 40553816; PMCID: PMC12831084.

BLACKMON SH

Abou Chaar MK, Alwatari Y, Corl FM, Aldin ST, Mardini S, Blackmon SH. Complex Esophageal Reconstruction: Challenges and Techniques. *Ann Thorac Surg.* 2025 Aug;120(2):244-255. doi: 10.1016/j.athoracsur.2025.02.028. Epub 2025 Apr 22. PMID: 40274211.

Price EL, Blackmon SH, Jagsi R. Connecting Through Cancer: Overcoming Distress and Isolation Together. *Am Soc Clin Oncol Educ Book.* 2025 Jun;45(3):e474562. doi: 10.1200/EDBK-25-474562. Epub 2025 Jun 16. PMID: 40523206.

Pohlman A, Odeh AM, Purnell SM, Alrahmani L, Blackmon SH, Coughlin JM, Abdelsattar ZM. Comparing companion open access journals to their traditional journal counterparts. *Account Res.* 2025 Oct 18:1-12. doi: 10.1080/08989621.2025.2575211. Epub ahead of print. PMID: 41108186.

Lim E, Blackmon SH, Depypere L, Gonzalez M, Mitzman B, Stiles BM, Novoa N. Clinical outcomes of digital versus traditional chest drains after thoracic surgery: a narrative review of randomised trials. *J Thorac Dis.* 2025 Aug 31;17(8):6318-6325. doi: 10.21037/jtd-2025-298. Epub 2025 Aug 25. PMID: 40950925; PMCID: PMC12433118.

Cangut B, Molena D, Worrell SG, Blackmon S, Antonoff MB. Women in Cardiothoracic Surgery: Impact on Partners, Coparents, and Children. *Ann Thorac Surg Short Rep.* 2024 Oct 30;3(2):528-533. doi: 10.1016/j.atsrs.2024.10.010. PMID: 40525188; PMCID: PMC12167519.

Shekar A, Hart V, Treffalls J, Miles TJ, Rosengart TK, Moon MR, Coselli JS, Barron LM, Groth SS, Blackmon SH, Ghanta RK, Hui DS, Chatterjee S. The state of educational research in cardiothoracic surgery: A review of the literature. *JTCVS Open.* 2025 Oct 24;28:728-735. doi: 10.1016/j.xjon.2025.10.010. PMID: 41473093; PMCID: PMC12745122.

Cangut B, Sakowitz S, Rajah T, Papageorge M, Boyd R, Lin N, Stanley M, Blackmon S, Molena D, Watkins A, Worrell SG, Antonoff MB. Celebrating the unseen benefits of surgical careers for mothers in cardiothoracic surgery. *JTCVS Open.* 2025 Feb 21;25:516-524. doi: 10.1016/j.xjon.2025.02.009. PMID: 40631037; PMCID: PMC12230452.

Patel MR, Begnaud A, Blackmon SH, Dudek AZ, Fujioka N, Harewood JCK, Jänne PA, Kern S, Hawk LR, Rusk AM, Wilder FG, Winn R, Torrison N, Searle S. Improving Patient Understanding and Outcomes in Lung Cancer Using an Animated Patient’s Guide with Visual Formats of Learning. *J Cancer Educ.* 2025 Jun;40(3):377-387. doi: 10.1007/s13187-024-02517-7. Epub 2024 Oct 22. PMID: 39438400; PMCID: PMC12176915.

CHAROENPONG P

Siddiqui NA, Charoenpong P. Pulmonary Venous Occlusive Disease. 2023 Jul 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 36256776.

Hong JP, Lee CH, Hong CT, Chan L, Chung CC, Charoenpong P, Chiu HC, Liou TH. Assessment of functioning using the WHODAS 2.0 among people with myasthenia gravis-associated disability: a nationwide follow-up study. *BMC Public Health.* 2025 Jul 2;25(1):2210. doi: 10.1186/s12889-025-23328-5. PMID: 40604668; PMCID: PMC12220094.

Yazdi A, Ramirez A, Walter RE, Charoenpong P. The Impact of Body Mass Index on Survival and Clinical Outcomes in Pulmonary Arterial Hypertension: Revisiting the Obesity Paradox. *Cureus.* 2025 Oct 26;17(10):e95467. doi: 10.7759/cureus.95467. PMID: 41322909; PMCID: PMC12658844.

CHATTERJEE S

Grant MC, Brudney CS, Hernandez-Montfort J, Ibekwe SO, Rea A, Stoppe C, Zarbock A, Shaw AD, Engelman DT, Kanwar MK; PeriOperative Quality Initiative (POQI) and the Enhanced Recovery After Surgery (ERAS) Cardiac Society workgroup; Chatterjee S. Definitions of Cardiogenic Shock and Indications for Temporary Mechanical Circulatory Support: Joint Consensus Report of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society. *Ann Thorac Surg.* 2025 Aug;120(2):202-212. doi:10.1016/j.athoracsur.2025.01.040. Epub 2025 Apr 3. PMID: 40187589.

Wieruszewski PM, Brinkman HM, Ortoleva JP, Ripoll JG, Pieterick SE, Damico KE, Chatterjee S, Wittwer ED, Gerberi DJ, D’Andria Ursileo J, Wieruszewski ED, Seelhammer TG. Dosing Reliability of Direct Thrombin Inhibitors in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis. *ASAIO J.* 2025 Sep 1;71(9):691-700. doi:10.1097/MAT.0000000000002512. Epub 2025 Jul 17. PMID: 40673548.

Miles TJ, Guinn MT, Suero OR, Rosengart TK, Moon MR, Coselli JS, Ghanta RK, Chatterjee S. Association between timing of angiotensin II administration and outcomes in vasoplegia after cardiac surgery. *JTCVS Open.* 2025 Apr 25;25:280-293. doi:10.1016/j.xjon.2025.04.014. PMID: 40631005; PMCID: PMC12230574.

Blackburn KW, Chatterjee S. Commentary: Cutting through the noise: Can natural language processing improve literature review in cardiac surgery? *J Thorac Cardiovasc Surg.* 2025 Sep;170(3):802-803. doi:10.1016/j.jtcvs.2024.10.006. Epub 2024 Oct 9. PMID: 39393629.

Blackburn KW, Nichols A, Karla A, Mohan N, Hingtgen A, Green SY, Nguyen LH, Weldon SA, Xue A, Orozco-Sevilla V, Chatterjee S, Moon MR, Coselli JS. Predicting perioperative risk of persistent paraplegia from preoperative factors in patients who undergo elective, open thoracoabdominal aortic aneurysm repair. *J Thorac Cardiovasc Surg.* 2025 Nov;170(5):1345-1352. e5. doi:10.1016/j.jtcvs.2025.04.001. Epub 2025 May 3. PMID: 40317286.

Miles TJ, Guinn MT, Tan X, Qi H, Orozco-Sevilla V, Moon MR, Coselli JS, Rosengart TK, Li M, Chatterjee S, Ghanta RK. Tissue perfusion pressure: A novel hemodynamic measure to assess risk of acute kidney injury after cardiac surgery. *J Thorac Cardiovasc Surg.* 2026 Feb;171(2):455-462.e3. doi:10.1016/j.jtcvs.2025.07.009. Epub 2025 Jul 16. PMID: 40680825.

Spelde AE, Barron LM, Cangut B, Hickey GW, Lorusso R, Silvestry SC, Tong MZ, Engelman DT, Shaw AD, Chatterjee S; PeriOperative Quality Initiative (POQI) and the Enhanced Recovery After Surgery (ERAS) Cardiac Society Workgroup. Escalation and De-escalation of Temporary Mechanical Circulatory Support: Joint Consensus Report of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society. *Ann Thorac Surg.* 2025 Aug;120(2):213-224. doi:10.1016/j.athoracsur.2025.01.038. Epub 2025 Apr 3. PMID: 40187586.

Grant MC, Kanwar MK, Spelde AE, Chatterjee S, Deschamps J, Arora RC, Shaw AD, Engelman DT; PeriOperative Quality Initiative (POQI) and the Enhanced Recovery After Surgery (ERAS) Cardiac Society workgroup. Temporary Mechanical Circulatory Support in Cardiogenic Shock: Executive Summary of the Joint Consensus Reports of the PeriOperative Quality Initiative and the Enhanced Recovery After Surgery Cardiac Society. *Ann Thorac Surg.* 2025 Aug;120(2):194-201. doi:10.1016/j.athoracsur.2025.03.024. Epub 2025 Apr 2. PMID: 40185355.

Arora RC, Chatterjee S, Milewski R, Baciewicz FA, Haft J, Martin L. 2022: Perioperative and critical care year in review for the cardiothoracic surgery team. *J Thorac Cardiovasc Surg.* 2025 Jul;170(1):279-286. doi:10.1016/j.jtcvs.2024.05.011. Epub 2024 May 23. PMID: 38795907.

Wieruszewski PM, Ortoleva JP, Bauer SR, Ripoll JG, Chatterjee S, Gerberi DJ, Wieruszewski ED, Stephens EH, Joyner MJ, Wittwer ED. Definitions for Vasoplegia Associated With On-Pump Cardiac Surgery: A Systematic Review With Meta-Analysis. *Crit Care Explor.* 2025 Dec 18;7(12):e1361. doi:10.1097/CCE.0000000000001361. PMID: 41410546.

Rhoades BD, Martinez GE, Glover V, Tran TT, Green SY, Chatterjee S, Moon MR, Coselli JS. Surgical Intervention Among Heritable Thoracic Aortic Disease Parent-Child Dyads. *Ann Thorac Surg.* 2026 Apr;121(4):864-870. doi:10.1016/j.athoracsur.2025.09.017. Epub 2025 Nov 11. PMID: 41075997.

Miles TJ, Guinn MT, Ghanta RK, Chatterjee S. The Vasoplegia Risk Score: A Key Step Toward Individualized Vasoplegia Risk Assessment. *Ann Thorac Surg.* 2025 Dec 2:S0003-4975(25)01182-8. doi:10.1016/j.athoracsur.2025.11.024. Epub ahead of print. PMID: 41344421.

Suzuki Y, Radhakrishnan R, Mao RD, Ryan J, Wisniewski A, Carrott P, Chan EG, Lynch W, Loor G, Chatterjee S, Furukawa M, Sanchez PG. Extracorporeal membrane oxygenation after lung transplant: An ELSO registry analysis. *Perfusion.* 2025 Nov;40(8):1780-1788. doi:10.1177/02676591251331158. Epub 2025 Mar 28. PMID: 40155315.

Shekar A, Hart V, Treffalls J, Miles TJ, Rosengart TK, Moon MR, Coselli JS, Barron LM, Groth SS, Blackmon SH, Ghanta RK, Hui DS, Chatterjee S. The state of educational research in cardiothoracic surgery: A review of the literature. *JTCVS Open.* 2025 Oct 24;28:728-735. doi:10.1016/j.xjon.2025.10.010. PMID: 41473093; PMCID: PMC12745122.

Miles TJ, Ghanta RK, Chatterjee S. Correct Diagnosis Is Critical to Managing Vasoplegia After Cardiac Surgery. *Ann Thorac Surg.* 2026 Jan;121(1):259-260. doi:10.1016/j.athoracsur.2025.06.005. Epub 2025 Jun 21. PMID: 40545022.

Brlecic PE, Sylvester CB, Hogan KJ, Zhang Q, Coselli JS, Moon MR, Rosengart TK, Chatterjee S, Ghanta RK. Low socioeconomic status adversely influences outcomes after coronary artery bypass grafting. *J Thorac Cardiovasc Surg.* 2025 Nov;170(5):1480-1490.e5. doi:10.1016/j.jtcvs.2025.01.010. Epub 2025 Jan 19. PMID: 39837409; PMCID: PMC13061371.

Miles TJ, Guinn MT, Suero OR, Rosengart TK, Moon MR, Coselli JS, Ghanta RK, Chatterjee S. A Novel Clinical Risk Score to Predict Vasoplegia After Adult Cardiac Surgery. *Ann Thorac Surg.* 2025 Oct;120(4):705-712. doi:10.1016/j.athoracsur.2025.02.022. Epub 2025 Mar 20. PMID: 40120788.

Nguyen A, Civitello A, Shafii A, Loor G, Chatterjee S, Frazier OH, Liao K. Evolution of Gastrointestinal Bleeding in Patients Supported With Continuous-Flow Left Ventricular Assist Devices. *ASAIO J.* 2025 Oct 31. doi:10.1097/MAT.0000000000002597. Epub ahead of print. PMID: 41168144.

Nichols A, Blackburn KW, Glover VA, Nguyen LH, Etheridge GM, Green SY, Barron LK, Xue AH, Chatterjee S, Orozco-Sevilla V, Moon MR, Coselli JS. Outcomes of thoracoabdominal aortic aneurysm repair in patients with and without peripheral arterial disease. *J Thorac Cardiovasc Surg.* 2025 Nov;170(5):1371-1378.e6. doi:10.1016/j.jtcvs.2025.03.009. Epub 2025 Mar 18. PMID: 40112948. CORNWELL LD

Salna M, Bavaria JE, Heimansohn D, Beaver T, Griffith B, Svensson LG, Pibarot P, Borger MA, Thourani VH, Blackstone EH, Cornwell LD, Puskas JD, Takayama H. Seven-Year Results for RESILIA Tissue in Bicuspid Aortic Valve Replacement Patients: Age and Valve Size Considerations. *Interdiscip Cardiovasc Thorac Surg.* 2025 Aug 5;40(8):ivaf176. doi:10.1093/icvts/ivaf176. PMID: 40748697; PMCID: PMC12342796.

Volk L, Cornwell L, Pajaro O, Kolodziejski P, Wisnowski J, Walder A, Schutz AB. Arterial graft choice and outcomes within the Veterans Administration: A 20-year review of 47,525 patients. *J Thorac Cardiovasc Surg.* 2026 Apr;171(4):936-943.e1. doi:10.1016/j.jtcvs.2025.09.055. Epub 2025 Oct 17. PMID: 41110500.

DEVARAJAN SR

Mohanty M, Leiras C, Sun H, Rau R, Fastenau J, Feliciano J, Devarajan SR. Frequency, duration, and cost of pulmonary exacerbations among patients with bronchiectasis. *J Med Econ.* 2025 Dec;28(1):1798-1810. doi:10.1080/13669998.2025.2567761. Epub 2025 Oct 14. PMID: 41017477.

Shehab M, Al-Fajri S, Alanqar A, Alborom M, Alrashed F, Alshammaa F, Alfadhli A, Devarajan S, Alkhairi I, Cherian P, Abubaker J, Abu-Farha M, Al-

Mulla F. Impact of Tumor Necrosis Factor Antagonist Therapy on Circulating Angiopoietin-like Protein 8 (ANGPTL8) Levels in Crohn’s Disease-A Prospective Multi-Center Study. *J Clin Med.* 2025 Jul 15;14(14):5006. doi:10.3390/jcm14145006. PMID: 40725697; PMCID: PMC12295380.

Ramanujam H, Ramalingam M, Refaya AK, Rajendran P, Baskar M, Palanivel N, Devarajan S, Balasubramaniam A, Nithya R, Shanmugam S, Palaniyandi K. Genomic insights into Mycobacterium orygis in wild ungulates in Chennai, India. *Infect Genet Evol.* 2026 Jan;137:105869. doi:10.1016/j.meegid.2025.105869. Epub 2025 Dec 19. PMID: 41423185.

Devarajan S, Rdesinski R, Sweeney S, Onishi E, Gallivan E, Krulewicz H, Izumi S. Impact of nurse-led advance care planning in a primary care setting. *Palliat Support Care.* 2026 May 12;24:e140. doi:10.1017/S1478951526102508. PMID: 42117191.

Yousef R, Alkazemi DUZ, Abu-Farha M, Abubaker J, Devarajan S, Rahman A, Al-Mulla F. Associations of TAS1R2 and TAS2R38 Genetic Variants with Sugar-Sweetened Beverage Intake and Obesity Risk in Kuwaiti Adolescents: A Cross-Sectional Study. *Children (Basel).* 2025 Sep 8;12(9):1192. doi:10.3390/children12091192. PMID: 41007057; PMCID: PMC12469038.

Suresh R, Sujatha C, Saju AP, Sujatha A, Nair ANK, Rema PP, Devarajan S, Usha A, Krishnankutty SL, Anish TS. Antibody response following rabies vaccination: a retrospective cohort study from a tertiary centre in Kerala, India. *Trans R Soc Trop Med Hyg.* 2026 May 9:trag055. doi:10.1093/trstmh/trag055. Epub ahead of print. PMID: 42104810.

Alqaderi H, Batorsky R, Azar G, Malik MZ, Nizam R, Altabtbaei K, Devarajan S, Ahmad R, Michaud DS, Zhao N, Zavras A, Al-Mulla F. Comparative machine learning analysis of saliva and plaque microbiomes in Kuwaitis with type 1 diabetes. *Front Microbiol.* 2026 Mar 27;17:1735375. doi:10.3389/fmicb.2026.1735375. PMID: 41971337; PMCID: PMC13066184.

DVORACEK LA

Beiriger JW, Tao W, Irgebay Z, Smetona J, Dvoracek L, Kass NM, Dixon A, Zhang C, Mehta M, Whitaker R, Goldstein JA. A Longitudinal Analysis of Pre- and Post-Operative Dysmorphology in Metopic Craniosynostosis. *Cleft Palate Craniofac J.* 2025 Jul;62(7):1144-1150. doi:10.1177/10556656241237605. Epub 2024 Mar 14. PMID: 38483822.

Dvoracek LA, Owens WR, Mohan VC, Abu-Ghname AMS, Pryor H. Surgical Reconstruction of Ulcers in Chronic Granulomatous Disease. *Plast Reconstr Surg Glob Open.* 2026 Mar 27;14(3):e7596. doi:10.1097/GOX.00000000000007596. PMID: 41907076; PMCID: PMC13023715.

Cheng LG, Liu SX, Dhariwal A, Glenney AE, Ocasio-Nieves B, Somorin T, Kass NM, Dvoracek LA, David JA, Kueper J, Saladino RA, Goldstein JA. Predictors and economic impact of potentially avoidable transfers in facial fractures among pediatric populations: A 15-year analysis. *Am J Emerg Med.* 2026 Apr 7;106:69-75. doi:10.1016/j.ajem.2026.04.007. Epub ahead of print. PMID: 42085947.

Camison L, Dvoracek LA, Bruce MK, Beiriger JW, Anstadt EE, Tamber MS, Goldstein JA, Losee JE. Long-term Outcomes of Porous Polyethylene Cranioplasty for Large Cranial Defects in Children: Assessment of Clinical Results and Cranial Growth. *Cleft Palate Craniofac J.* 2026 May 4:10556656261443448. doi:10.1177/10556656261443448. Epub ahead of print. PMID: 42080927.

FERNANDEZ R

Padhye AA, Guffey D, Leon-Pena A, Segraves J, Fernandez R 2nd, Loor G, Garcha P, Wu TD, Li G. Antithymocyte globulin therapy in chronic lung allograft dysfunction. *Front Transplant.* 2025 Jul 4;4:1607678. doi:10.3389/fitra.2025.1607678. PMID: 40687845; PMCID: PMC12271178.

Sela M, Roberts E, He ZMS, Li S, Thirukonda K, Sarlin S, Ramirez J, Fernandez R 2nd, Rana A. Improved outcomes in adult lung transplantation: a two-decade national analysis. *Heart Lung.* 2026 May 5;79:102833. doi:10.1016/j.hrtlng.2026.102833. Epub ahead of print. PMID: 42090899.

GROTH SS

Jang HJ, Patel M, Wang DY, Kang SW, Choi JM, Lee C, Vilchis M, Shim JS, Mitra S, Ranchod P, Kuncheria A, Hudson W, Jindra P, Lenge De Rosen V, Ramineni M, Camp ER, Kheradmand F, Ripley RT, Groth SS, Lee HS, Burt BM. Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma. Clin Cancer Res. 2025 Jul 1;31(13):2639-2654. doi:10.1158/1078-0432.CCR-24-4024. PMID: 40208070; PMCID: PMC12237568.

Chounoune R, Groth SS. Commentary: Planned or salvage esophagectomy versus definitive chemoradiation for esophageal squamous cell carcinoma: Is the photon mightier than the sword? J Thorac Cardiovasc Surg. 2025 Nov;170(5):1282-1283. doi:10.1016/j.jtcvs.2025.04.010. Epub 2025 Apr 11. PMID: 40222397.

Ito A, Kang SW, Jang HJ, Shim JS, Lee C, Ranchod P, Lee G, Mitra S, Jeon J, Syarif AH, Zhang Y, Byun J, Han Y, Malo J, Patel M, Ripley RT, Groth SS, Kheradmand F, Burt BM, Polverino F, Amos CI, Lee HS. Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2026 Mar 4:S0022-5223(26)00187-X. doi:10.1016/j.jtcvs.2026.02.030. Epub ahead of print. PMID: 41791482.

Shekar A, Hart V, Treffalls J, Miles TJ, Rosengart TK, Moon MR, Coselli JS, Barron LM, Groth SS, Blackmon SH, Ghanta RK, Hui DS, Chatterjee S. The state of educational research in cardiothoracic surgery: A review of the literature. JTCVS Open. 2025 Oct 24;28:728-735. doi:10.1016/j.xjon.2025.10.010. PMID: 41473093; PMCID: PMC12745122.

HANANIA NA

COPDGene 2025 Diagnosis Working Group and CanCOLD Investigators; Bhatt SP, Abadi E, Anzueto A, Bodduluri S, Casaburi R, Castaldi PJ, Cho MH, Comellas AP, Conrad DJ, Curtis JL, Dass C, DeMeo DL, Dransfield MT, San José Estépar R, Flenaugh EL, Foreman MG, Fortis S, Gupta A, Han MK, Hanania NA, Hersh CP, Hokanson JE, Humphries SM, Kirby M, Kunisaki KM, Li PZ, Lynch DA, MacIntyre NR, Make BJ, Mannino DM, Martinez FJ, McEvoy CE, Miller BE, Moll M, Nakhmani A, Newell JD Jr, Pratte KA, Regan EA, Reinhardt JM, Rennard SI, Rossiter HB, Strand MJ, Suri R, Wan ES, Wendt CH, Westney GE, Wilson CG, Wise RA, Young KA, Tan WC, Silverman EK, Crapo JD. A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease. JAMA. 2025 Jun 24;333(24):2164-2175. doi:10.1001/jama.2025.7358. PMID: 40382791; PMCID: PMC12086702.

Meulmeester FL, Mailhot-Larouche S, Celis-Preciado C, Lemaire-Paquette S, Ramakrishnan S, Wechsler ME, Brussels G, Corren J, Hardy J, Diver SE, Brightling CE, Castro M, Hanania NA, Jackson DJ, Martin N, Laugerud A, Santoro E, Compton C, Hardin ME, Holweg CTJ, Subhashini A, Hinks TSC, Beasley RW, Sont JK, Steyerberg EW, Pavord ID, Couillard S. Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025 Jun;13(6):505-516. doi:10.1016/S2213-2600(25)00037-2. Epub 2025 Apr 8. PMID: 40215991; PMCID: PMC12117016.

Wells JM, Krishnan JA, Wade RC, Kinney G, Wise RA, Neptune E, Polverino F, Hanania NA, Moll M, Königshoff M, Chandra D, Sciuuba F, Marchetti N, San José Estépar R, Diaz AA, El-Kersh K, Castro M, Zhang Y, Holbrook JT, Sugar EA, Kraft M, Kaner RJ, Make B, Rennard S. Post-COPD: Can Emphysema Be Repaired? Am J Respir Crit Care Med. 2025 Sep;211(9):1600-1609. doi:10.1164/rccm.202408-1602PP. PMID: 40498633; PMCID: PMC12756936.

Christenson SA, Hanania NA, Bhatt SP, Bafadhel M, Rabe KF, Vogelmeier CF, Papi A, Singh D, Laws E, Dakin P, Bansal A, Lu X, Bauer D, Maloney J, Robinson LB, Abdulai RM. Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Aug;13(8):687-697. doi:10.1016/S2213-2600(25)00044-X. Epub 2025 Jul 9. PMID: 40651490.

Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB. Effect of Dupilumab on Health-Related

Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS. Chest. 2025 Jul;168(1):56-66. doi:10.1016/j.chest.2025.01.029. Epub 2025 Jan 31. PMID: 39894389.

Canonica GW, Porsbjerg C, Price DB, Wechsler ME, Heaney LG, Hanania NA, Gall R, Pandit-Abid N, Jacob-Nara JA, Sacks HJ. Burden of Oral Corticosteroid Use in Severe Asthma: Challenges and Opportunities. Allergy. 2025 Aug;80(8):2113-2127. doi:10.1111/all.16569. Epub 2025 Jun 23. PMID: 40548588; PMCID: PMC12368757.

Lavere PF, Phillips KM, Hanania NA, Adrish M. Established and Emerging Asthma Biomarkers with a Focus on Biologic Trials: A Narrative Review. J Pers Med. 2025 Aug 13;15(8):370. doi:10.3390/jpm15080370. PMID: 40863432; PMCID: PMC12387636.

Cazzola M, Hanania NA, Rogliani P. Comorbidities as treatable traits of chronic airway diseases. Respir Med. 2025 Nov;248:108333. doi:10.1016/j.rmed.2025.108333. Epub 2025 Aug 29. PMID: 40886804.

Hanania NA, Herth FJF. Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils. Eur Respir Rev. 2025 Dec 10;34(178):250024. doi:10.1183/16000617.0024-2025. PMID: 41371716; PMCID: PMC12690368.

Phillips EK, Huang Y, Regan E, Make B, Strand M, Yohannes AM, Hanania NA, Bon J, Hoth KF, Crapo JD, Silverman EK, DeMeo DL. Frailty associates with respiratory exacerbations and mortality in the COPDGene cohort. Aging (Albany NY). 2025 Jul 3;17(7):1590-1623. doi:10.18632/aging.206275. Epub 2025 Jul 3. PMID: 40622758; PMCID: PMC12339021.

Schleich F, Oppenheimer JJ, Brussels G, Heaney LG, Busse WW, Lugogo NL, Hanania NA, Bonini M, Lommatzsch M, Chanez P, Vichiendilokkul A, Benson VS, Finney-Hayward T, Howarth P, Israel E. Asthma in the Biologics Era: Should Oral Corticosteroid Therapy Be Relegated to History? J Allergy Clin Immunol Pract. 2025 Jul;13(7):1559-1568. doi:10.1016/j.jaip.2025.04.007. Epub 2025 Apr 11. PMID: 40222631.

Hanania NA, Stanford R, Rendon A, Gemicioglu B, Fritscher L, Boonsawat W, Mamjudar A, Odo N, Hamouda M. Comparative effectiveness of inhaled fluticasone propionate/salmeterol and budesonide/formoterol fixed-dose combinations in asthma control - a retrospective United States database analysis. Respir Med. 2025 Aug-Sep;245:108172. doi:10.1016/j.rmed.2025.108172. Epub 2025 May 28. PMID: 40446865.

Cazzola M, Matera MG, Hanania NA, Rogliani P. Established and Emerging Biological Therapies for the Treatment of Comorbid Asthma and Chronic Obstructive Pulmonary Disease. J Inflamm Res. 2025 Dec 11;18:17319-17341. doi:10.2147/JIR.S552274. PMID: 41409564; PMCID: PMC12706161.

Bourdin A, Vlachaki I, Madoni A, Donhauser S, van der Deijl M, Chakrawarthy Manne M, Geddamura BG, Hanania NA. A systematic review of the humanistic, economic, sociodemographic, and environmental burden of severe/difficult-to-treat asthma. Curr Med Res Opin. 2025 Jun;41(6):1075-1095. doi:10.1080/03007995.2025.2513963. Epub 2025 Jun 18. PMID: 40501278.

Canonica GW, Ortega-Martell JA, Villarreal-González RV, Ansotegui IJ, Bachert C, Bernstein J, Bleecker E, Bondi B, Caminati M, Carr T, Cianferoni A, González ID, Díaz SG, Gómez RM, Hanania N, Heffler E, Nair P, Öztop N, Park HS, Pitè H, Rouadi P, Saito H, Triggiani M, Varricchi G, Virchow C, Yamada Y, Yáñez A, Morais-Almeida M. What is new on the horizon for the biologics world: New kids of the block - WAO state of art. World Allergy Organ J. 2026 Mar 6;19(3):101349. doi:10.1016/j.waojou.2026.101349. PMID: 41853324; PMCID: PMC12992511.

Hickman K, Tarabichi Y, Dickens AP, Pullen R, Kerr M, Couper A, Evans A, Gatenby J, Alves L, Ariti C, Bafadhel M, Carter V, Chalmers J, Chen R, Devereux G, Drummond MB, Gibson JM, Halpin DMG, Han M, Hanania NA, Hurst JR, Kaplan A, Kostikas K, Make B, Mapel D, Marshall J, Martinez F, Meldrum C, van Melle M, Miravittles M, Morris T, Mullerova H, Murray R, Muro S, Nordon C, Ohar J, Pace W, Pollack M, Quint JK, Sharma A, Singh D, Singh M, Trudo F, Williams D, Wilkinson T, Winders T, Price D. Pragmatic Evaluation of an Improvement Program for People Living With Modifiable High-Risk COPD Versus Usual Care: Protocols for the Cluster Randomized PREVAIL Trial. Chronic Obstr Pulm Dis. 2025 May

27;12(3):223-239. doi:10.15326/jcopdf.2024.0564. PMID: 40300198; PMCID: PMC12212362.

Riemann S, Meulmeester FL, Mailhot-Larouche S, Ramakrishnan S, Wechsler ME, Corren J, Diver SE, Brightling CE, Castro M, Hanania NA, Jackson DJ, Martin N, Laugerud A, Clarke D, Moore A, Hardin ME, Holweg CTJ, Allu S, Hinks TSC, Beasley RW, Sont JK, Steyerberg EW, Pavord ID, Brussels G, Couillard S; OxfoRd Asthma attaCk risk scaLE Meta-Analysis (ORACLE2) Consortium. Impact of Sex on Prediction of Asthma Attacks by Clinical Risk Factors and Type 2 Biomarkers. Chest. 2026 Jan 31:S0012-3692(26)00131-5. doi:10.1016/j.chest.2025.12.049. Epub ahead of print. PMID: 41621639.

Evans A, VanWyk J, Kerr M, Couper A, Pace WD, Tarabichi Y, Pullen R, Pollack M, Drummond MB, Ohar J, Meldrum C, Han MK, Kaplan A, Winders T, Wisnivesky J, Make B, Federman A, Carter V, Lang K, Mapel D, Hanania NA, Stolz D, Martinez FJ, Price D. Practical strategies for achieving system change in the US: lessons and insights from the CONQUEST quality improvement programme. Prim Health Care Res Dev. 2025 Jun 23;26:e50. doi:10.1017/S1463423625100170. PMID: 40546134; PMCID: PMC12188133.

Morais-Almeida M, Canonica GW, Giavina-Bianchi P, Arasi S, Caminati M, Fiocchi A, Fonacier LS, Giavina-Bianchi M, Gómez RM, González-Díaz SN, Martin BL, Ortega Martell JA, Pitè H, Rouadi P, Sánchez Caraballo J, Villarreal-González RV, Virchow JC, Bachert C, Bernstein JA, Cianferoni A, Dávila I, Hanania NA, Heffler E, Nair P, Park HS, Saito H, Varricchi G, Yáñez A, Ansotegui IJ. Clinical remission in allergy and clinical immunology practice: State of the art and World Allergy Organization (WAO) call to action. World Allergy Organ J. 2026 Apr 20;19(5):101383. doi:10.1016/j.waojou.2026.101383. PMID: 42058161; PMCID: PMC13122681.

Salas PS, Villareal DT, Tejwani V, Koirala A, Coarfá C, McCormack MC, Hanania NA, Wu TD. Hyperglycemia, receptor for advanced glycation end products, and small airways dysfunction in asthma. Ann Allergy Asthma Immunol. 2026 Feb;136(2):173-179.e3. doi:10.1016/j.anai.2025.10.023. Epub 2025 Oct 24. PMID: 41553201; PMCID: PMC12973237.

HEINLE JS

Tang RC, Cho J, Orr Y, Heinle JS, Tunuguntla HP, Tume SC, Teruya J, Adachi I. Berlin cannulation with an outflow interposition graft-a versatile technique. JTCVS Tech. 2025 Oct 15;35:102124. doi:10.1016/j.jxjc.2025.09.036. PMID: 41658916; PMCID: PMC12881816.

Kalustian AB, Ji P, Wadhwa L, Caldarone CA, Bansal M, Qureshi AM, Heinle JS, Birla RK. Insights into the molecular mechanism of pulmonary vein stenosis in pediatric patients with congenital heart disease. JTCVS Open. 2025 Apr 24;26:166-181. doi:10.1016/j.xjon.2025.04.012. PMID: 40923050; PMCID: PMC12414425.

Yoneyama F, Awori J, Sachdeva S, Jayakumar KA, Brenes J, Heinle JS. Surgical Repair of Double-Outlet Right Ventricle With Doubly Committed Juxtaarterial Ventricular Septal Defect: The Role of Virtual Reality. Ann Thorac Surg Short Rep. 2025 Aug 20;4(1):167-170. doi:10.1016/j.atsrr.2025.07.016. PMID: 42027485; PMCID: PMC13100757.

KHERADMAND F

Qualls AE, Tsao T, Lui I, Lim SA, Su Y, Chen E, Duchen D, Maecker HT, Kim-Schulze S, Montgomery RR, Krammer F, Langelier CR, Levy O, Baden LR, Melamed E, Ehrlich LI, McComsey GA, Sekaly RP, Cairns CB, Haddad EK, Shaw AC, Hafler DA, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Higuita NIA, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Fernandez-Sesma A, Simon V, Kraft M, Bime C, Calfee CS, Erle DJ, Schaeenmann J, Ozonoff A, Peters B, Kleinstein SH, Augustine AD, Diray-Arce J, Becker PM, Rouphael N; IMPACC Network; Goldman JD, Calabrese DR, Heath JR, Wells JA, Reed EF, Lanier LL, Pickering H, Aguilar OA. High-affinity CD16A polymorphism associated with reduced risk of severe COVID-19. JCI Insight. 2025 May 22;10(13):e191314. doi:10.1172/jci.insight.191314. PMID: 40402577; PMCID: PMC12306582.

Gabernet G, Maciuch J, Gygi JP, Moore JF, Hoch A, Syphurs C, Chu T, Doni Jayavelu N, Corry DB, Kheradmand F, Baden LR, Sekaly RP, McComsey GA, Haddad EK, Cairns CB, Rouphael N, Fernandez-Sesma A, Simon V, Metcalf JP, Agudelo Higuita NI, Hough CL, Messer WB, Davis MM, Nadeau KC,

Pulendran B, Kraft M, Bime C, Reed EF, Schaeenman J, Erle DJ, Calfee CS, Atkinson MA, Brakenridge SC, Melamed E, Shaw AC, Hafler DA, Augustine AD, Becker PM, Ozonoff A, Bosinger SE, Eckalbar W, Maecker HT, Kim-Schulze S, Steen H, Krammer F, Westendorf K; IMPACC Network; Peters B, Fourati S, Altman MC, Levy O, Smolen KK, Montgomery RR, Diray-Arce J, Kleinstein SH, Guan L, Ehrlich LI. A multiomics recovery factor predicts long COVID in the IMPACC study. J Clin Invest. 2025 Sep 9;135(21):e193698. doi:10.1172/JCI193698. PMID: 40924481; PMCID: PMC12582403.

Costa Monteiro AC, Pickering H, Sarma A, Taylor CS, Jenkins MM, Hsu FM, Nadel B, Levy O, Baden LR, Melamed E, Ehrlich LIR, McComsey GA, Sekaly RP, Cairns CB, Haddad EK, Shaw AC, Hafler DA, Montgomery RR, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Higuita NIA, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Geng LN, Fernandez-Sesma A, Simon V, Krammer F, Kraft M, Bime C, Calfee CS, Erle DJ, Bosinger S, Eckalbar W, Maecker H, Rahman A, Guan L, Peters B, Kleinstein SH, Augustine AD, Diray-Arce J, Becker PM, Rouphael N; IMPACC Network; CAPINT Site investigators of the PALISI Network; Agus M, Kulkarni H, Schaeenmann JM, Salchi-Rad R, Matthay MA, Reed EF, Sapru A. Circulating endothelial signatures correlate with worse outcomes in COVID-19, respiratory failure and ARDS. Crit Care. 2025 Oct 14;29(1):432. doi:10.1186/s13054-025-05596-0. PMID: 41088445; PMCID: PMC12522733.

Jang HJ, Patel M, Wang DY, Kang SW, Choi JM, Lee C, Vilchis M, Shim JS, Mitra S, Ranchod P, Kuncheria A, Hudson W, Jindra P, Lenge De Rosen V, Ramineni M, Camp ER, Kheradmand F, Ripley RT, Groth SS, Lee HS, Burt BM. Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma. Clin Cancer Res. 2025 Jul 1;31(13):2639-2654. doi:10.1158/1078-0432.CCR-24-4024. PMID: 40208070; PMCID: PMC12237568.

Jayavelu ND, Qi J, Milliren CE, Ozonoff A, Liu S, Levy O, Baden LR, Melamed E, McComsey GA, Cairns CB, Schaeenman J, Shaw AC, Hafler DA, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Agudelo Higuita NI, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Geng LN, Sesma AF, Simon V, Krammer F, Bime C, Calfee CS, Bosinger SE, Eckalbar W, Steen H, Maecker HT; IMPACC Network; Augustine AD, Diray-Arce J, Haddad EK, Sekaly RP, Kraft M, Woodruff PG, Erle DJ, Ehrlich LIR, Montgomery RR, Becker PM, Altman MC, Fourati S. Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort. J Allergy Clin Immunol Glob. 2025 Jun 12;4(4):100515. doi:10.1016/j.jacig.2025.100515. PMID: 40709330; PMCID: PMC12284355.

Doni Jayavelu N, Samaha H, Wimalasena ST, Hoch A, Gygi JP, Gabernet G, Ozonoff A, Liu S, Milliren CE, Levy O, Baden LR, Melamed E, Ehrlich LIR, McComsey GA, Sekaly RP, Cairns CB, Haddad EK, Schaeenman J, Shaw AC, Hafler DA, Montgomery RR, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Agudelo Higuít NI, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Geng LN, Fernandez Sesma A, Simon V, Krammer F, Kraft M, Bime C, Calfee CS, Erle DJ, Langelier CR; IMPACC Network; Guan L, Maecker HT, Peters B, Kleinstein SH, Reed EF, Augustine AD, Diray-Arce J, Becker PM, Rouphael N, Altman MC. Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors. Commun Med (Lond). 2026 Jan 3;6(1):1. doi:10.1038/s43856-025-01230-w. Erratum in: Commun Med (Lond). 2026 Feb 23;6(1):125. doi:10.1038/s43856-026-01425-9. PMID: 41484172; PMCID: PMC12764860.

Pickering H, Alipanah-Lechner N, Chen E, Duchen D, Maecker HT, Kim-Schulze S, Montgomery RR, Cotsapas C, Steen H, Krammer F, Langelier CR, Levy O, Baden LR, Melamed E, Ehrlich LI, McComsey GA, Sekaly RP, Cairns CB, Haddad EK, Shaw AC, Hafler DA, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Higuita NIA, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Sesma AF, Simon V, Kraft M, Bime C, Erle DJ, Schaeenmann J, Ozonoff A, Peters B, Kleinstein SH, Augustine AD, Diray-Arce J, Becker PM, Rouphael N, Altman MC, Bosinger S, Eckalbar W; IMPACC Network; Calfee CS, Aguilar OA, Reed EF, Greenland JR, Calabrese DR. MICBG406A polymorphism reduces risk of mechanical ventilation and death during viral acute lung injury. JCI Insight. 2025 Jul 3;10(15):e191951. doi:10.1172/jci.insight.191951. PMID: 40608426; PMCID: PMC12333951.

Glacock A, Maguire C, Phan HV, Lydon EC, Schaenman J, Calfee CS, Melamed E, Greenland J, Corry DB, Kheradmand F, Baden LR, Sekaly R, McComsey GA, Haddad EK, Cairns CB, Geng LN, Pulendran B, Fernandez-Sesma A, Simon V, Metcalf JP, Agudelo Higuita NI, Messer WB, Davis MM, Nadeau KC, Kraft M, Bime C, Erle DJ, Atkinson MA, Brakenridge SC, Ehrlich LIR, Montgomery RR, Shaw AC, Hough CL, Hafler DA, Augustine AD, Becker PM, Peters B, Ozonoff A, Hoch A, Kim-Schulze S, Krammer F, Bosinger S, Eckalbar W, Altman MC, Wilson M, Guan L, Maecker H, Steen H; IMPACC Network; Diray-Arce J, Roupheel N, Kleinstein SH, Jayavelu ND, Reed EF, Levy O, Chu VT, Langelier CR. Empiric azithromycin alters the upper respiratory microbiome and resistome without anti-inflammatory benefit in COVID-19. *Nat Microbiol.* 2026 Apr;11(4):1100-1112. doi:10.1038/s41564-026-02285-8. Epub 2026 Mar 16. PMID: 41840216; PMCID: PMC13056551.

Chandrakantan A, Williamson MR, Krishnan V, Hedayatpour MJ, Adler AC, Adyapak N, Ward CS, Ray R, Durgan D, Kheradmand F, Deneen B. Neurodevelopmental abnormalities underlying behavioral deficits in a model of pediatric obstructive sleep apnea. *Exp Neurol.* 2025 Nov;393:115418. doi:10.1016/j.expneurol.2025.115418. Epub 2025 Aug 12. PMID: 40812498; PMCID: PMC13052470.

Hosseini R, Garshick E, Slade MD, Timmons A, Korpak AM, Smith NL, Nakayama KS, Baird CP, Ciminera P, Kheradmand F, Fan VS, Hart JE, Koutrakis P, Kuschner WG, Ioachimescu OC, Jerrett M, Montgrain PR, Proctor SP, Wendt CH, Wongtrakool C, Wan ES, Blanc PD, Redlich CA. Military Inhalational Exposures Outside the Theater of Conflict and Chronic Respiratory Symptoms. *JAMA Netw Open.* 2025 Jul 1;8(7):e2522080. doi:10.1001/jamanetworkopen.2025.22080. PMID: 40690216; PMCID: PMC12281241.

Abe K, Holmes TH, Nguyen TT; IMPACC Network; Kim-Schulze S, Levy O, Baden LR, Melamed E, Ehrlich LIR, McComsey GA, Sekaly RP, Cairns CB, Haddad EK, Shaw AC, Hafler DA, Montgomery RR, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Agudelo Higuita NI, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Fernandez-Sesma A, Simon V, Kraft M, Bime C, Calfee CS, Erle DJ, Schaenman J, Reed EF, Ozonoff A, Peters B, Kleinstein SH, Augustine AD, Diray-Arce J, Becker PM, Roupheel N, Maecker HT. Evaluating COVID-19 severity prediction and immune dynamics with NULISAseq: Insights from the IMPACC study. *J Immunol.* 2025 Dec 1;214(12):3310-3320. doi:10.1093/jimmun/vkaf263. PMID: 41166719; PMCID: PMC12726064.

Hou J, Haslund-Gourley B, Diray-Arce J, Hoch A, Roupheel N, Becker PM, Augustine AD, Ozonoff A, Guan L, Kleinstein SH, Peters B, Reed E, Altman M, Langelier CR, Maecker H, Kim S, Montgomery RR, Krammer F, Wilson M, Eckalbar W, Bosinger SE, Levy O, Steen H, Rosen LB, Baden LR, Melamed E, Ehrlich LIR, McComsey GA, Sekaly RP, Schaenman J, Shaw AC, Hafler DA, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Agudelo Higuita NI, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Fernandez Sesma A, Simon V, Kraft M, Bime C, Calfee CS, Erle DJ, Impacc Network, Robinson LF, Cairns CB, Haddad EK, Comunale MA. Baseline predictors for 28-day COVID-19 severity and mortality among hospitalized patients: results from the IMPACC study. *Front Med (Lausanne).* 2025 Jul 4;12:1604388. doi:10.3389/fmed.2025.1604388. PMID: 40687705; PMCID: PMC12271175.

Mauk KE, Miramón P, Lorenz MC, Lortal L, Naglik JR, Hube B, Bimler L, Kheradmand F, Corry DB. Commensal colonization of *Candida albicans* in the mouse gastrointestinal tract is mediated via expression of candidalysin and adhesins. *Microbiol Spectr.* 2025 Sep 2;13(9):e0056725. doi:10.1128/spectrum.00567-25. Epub 2025 Jul 30. PMID: 40736264; PMCID: PMC12403622.

Zhang Y, Sauler M, Corry DB, Ochsner SA, Perusich S, Song LZ, Malo J, Estepar RSJ, Polverino F, Kheradmand F. Lung NR3C1+ and CXCR6high T cells distinguish immunopathogenesis of human emphysema. *Commun Biol.* 2025 Sep 24;8(1):1353. doi:10.1038/s42003-025-08698-1. PMID: 40993192; PMCID: PMC12460644.

Langelier C, Glascock A, Maguire C, Van Phan H, Lydon E, Calfee C, Corry D, Kheradmand F, Baden L, Sekaly RP, McComsey G, Haddad E, Cairns C, Pulendran B, Fernandez-Sesma A, Simon V, Metcalf J, Higuita N, Messer W, Davis M, Nadeau KC, Kraft M, Bime C, Schaenman J, Erle D, Atkinson M, Ehrlich LIR, Melamed E, Montgomery R, Shaw A, Hough C, Geng L, Hoch

A, Hafler D, Augustine A, Becker P, Peters B, Ozonoff A, Kim-Schulze S, Krammer F, Bosinger S, Eckalbar W, Altman M, Wilson M, Guan L, Maecker H, Steen H, Diray-Arce J, Roupheel N, Kleinstein S, Reed E, Levy O, Chu V. Empiric Azithromycin in COVID-19 Impacts the Respiratory Microbiome and Antimicrobial Resistome without Anti-inflammatory Benefit. *Res Sq [Preprint].* 2025 Jun 20:rs.3.rs-6875205. doi:10.12103/rs.3.rs-6875205/v1. Update in: *Nat Microbiol.* 2026 Apr;11(4):1100-1112. doi:10.1038/s41564-026-02285-8. PMID: 40585204; PMCID: PMC12204364.

Doni Jayavelu N, Samaha H, Wimalasena ST, Hoch A, Gygi JP, Gabernet G, Ozonoff A, Liu S, Milliren CE, Levy O, Baden LR, Melamed E, Ehrlich LIR, McComsey GA, Sekaly RP, Cairns CB, Haddad EK, Schaenman J, Shaw AC, Hafler DA, Montgomery RR, Corry DB, Kheradmand F, Atkinson MA, Brakenridge SC, Agudelo Higuít NI, Metcalf JP, Hough CL, Messer WB, Pulendran B, Nadeau KC, Davis MM, Geng LN, Fernandez Sesma A, Simon V, Krammer F, Kraft M, Bime C, Calfee CS, Erle DJ, Langelier CR; IMPACC Network; Guan L, Maecker HT, Peters B, Kleinstein SH, Reed EF, Augustine AD, Diray-Arce J, Becker PM, Roupheel N, Altman MC. Author Correction: Machine learning models predict long COVID outcomes based on baseline clinical and immunologic factors. *Commun Med (Lond).* 2026 Feb 23;6(1):125. doi:10.1038/s43856-026-01425-9. Erratum for: *Commun Med (Lond).* 2026 Jan 3;6(1):1. doi:10.1038/s43856-025-01230-w. PMID: 41730996; PMCID: PMC12929789.

Ito A, Kang SW, Jang HJ, Shim JS, Lee C, Ranchod P, Lee G, Mitra S, Jeon J, Syarif AH, Zhang Y, Byun J, Han Y, Malo J, Patel M, Ripley RT, Groth SS, Kheradmand F, Burt BM, Polverino F, Amos CI, Lee HS. Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer. *J Thorac Cardiovasc Surg.* 2026 Mar 4:S0022-5223(26)00187-X. doi:10.1016/j.jtcvs.2026.02.030. Epub ahead of print. PMID: 41791482.

Ito A, Kang SW, Jang HJ, Shim JS, Lee C, Ranchod P, Lee G, Mitra S, Jeon J, Syarif AH, Zhang Y, Byun J, Han Y, Malo J, Patel M, Ripley RT, Groth SS, Kheradmand F, Burt BM, Polverino F, Amos CI, Lee HS. Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer. *bioRxiv [Preprint].* 2026 Jan 2:2026.01.01.696292. doi:10.64898/2026.01.01.696292. Update in: *J Thorac Cardiovasc Surg.* 2026 Mar 4:S0022-5223(26)00187-X. doi:10.1016/j.jtcvs.2026.02.030. PMID: 41509400; PMCID: PMC12776338.

Doni Jayavelu N, Qi JJ, Fourati S, Kheradmand F, Langelier CR, Ehrlich LIR, Diray-Arce J, Hoch A, Kraft M, Becker PM, Altman MC, Montgomery RR. Airway Immune Signatures in Severe and Fatal Infection with COVID-19. *Am J Respir Cell Mol Biol.* 2025 Jun;72(6):708-712. doi:10.1165/rcmb.2024-0462LE. PMID: 40444914; PMCID: PMC12143404.

LEE HS

Byun J, Han Y, Choi J, Sun R, Shaw VR, Zhu C, Xiao X, Lusk C, Badr H, Lee HS, Jang HJ, Li Y, Lim H, Long E, Liu Y, Kachuri L, Walsh KM, Wiencke JK, Albanes D, Lam S, Tardon A, Neuhouser ML, Barnett MJ, Chen C, Bojesen S, Brenner H, Landi MT, Johansson M, Risch A, Wichmann HE, Bickeböller H, Christiani DC, Rennert G, Arnold S, Field JK, Shete S, Le Marchand L, Liu G, Andrew AS, Zienolddiny S, Grankvist K, Johansson M, Caporaso N, Taylor F, Lazarus P, Schabath MB, Aldrich MC, Patel A, Lin X, Zanetti KA, Harris CC, Chanock S, McKay J, Schwartz AG, Hung RJ, Amos CI; INTEGRAL-ILCCO Consortium. Genome-wide association study for lung cancer in 6531 African Americans reveals new susceptibility loci. *Hum Mol Genet.* 2025 Jul 3;34(14):1227-1237. doi:10.1093/hmg/ddaf059. PMID: 40341939; PMCID: PMC12407114.

Yao J, Shim JS, Wong K, Zhu J, Liu Y, Kang SW, Burt KBM, Choi JM, Lee C, Julio ICL, Soto LMS, Hernandez S, Colbert K, Lu W, Khan K, Mansfield PF, Jang HJ, Yue T, Li C, Zhu H, Wang L, Lee HS, Wang T. An Interpretable Multi-instance Learner Decodes Cellular Recruitment from Spatially Resolved Transcriptomics. *bioRxiv [Preprint].* 2025 Dec 23:2025.11.20.689581. doi:10.1101/2025.11.20.689581. PMID: 41332779; PMCID: PMC12667933.

Tan T, Shaw VR, Byun J, Lee HS, Han Y, Li Y, Hung RJ, Christiani DC, Wang XA, Johansson M, Xiao X, Zaridze D, Bojesen SE, Shete S, Albanes D, Aldrich MC, Tardon A, Fernandez-Tardon G, Le Marchand L, Rennert G, Bickeböller H, Wichmann HE, Risch A, Field JK, Davies M, Woll P, Kiemeney LA, Haugen A, Zienolddiny S, Lam S, Johansson M, Grankvist K, Schabath MB, Andrew

A, Lazarus P, Arnold SM, Zhu D, Landi MT, McKay J, Amos C, Cheng C. Germline HLA heterozygosity is associated with decreased lung cancer risk. *HGG Adv.* 2026 Apr 9;7(2):100567. doi:10.1016/j.xhgg.2026.100567. Epub 2026 Jan 12. PMID: 41530975; PMCID: PMC12860938.

Gorlova OY, Gorlov IP, Ripley RT, Cheng C, Li Y, Peng B, Liu Y, Jang HJ, Kang SW, Lee C, Ranchod P, Burt BM, Lee HS, Amos CI. Gene expression in tumor and adjacent normal tissues in lung adenocarcinoma subtypes. *BMC Cancer.* 2025 Jul 14;25(1):1169. doi:10.1186/s12885-025-14496-z. PMID: 40660181; PMCID: PMC12261662.

Ito A, Kang SW, Jang HJ, Shim JS, Lee C, Ranchod P, Lee G, Mitra S, Jeon J, Syarif AH, Zhang Y, Byun J, Han Y, Malo J, Patel M, Ripley RT, Groth SS, Kheradmand F, Burt BM, Polverino F, Amos CI, Lee HS. Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer. *J Thorac Cardiovasc Surg.* 2026 Mar 4:S0022-5223(26)00187-X. doi:10.1016/j.jtcvs.2026.02.030. Epub ahead of print. PMID: 41791482.

Ito A, Kang SW, Jang HJ, Shim JS, Lee C, Ranchod P, Lee G, Mitra S, Jeon J, Syarif AH, Zhang Y, Byun J, Han Y, Malo J, Patel M, Ripley RT, Groth SS, Kheradmand F, Burt BM, Polverino F, Amos CI, Lee HS. Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer. *bioRxiv [Preprint].* 2026 Jan 2:2026.01.01.696292. doi:10.64898/2026.01.01.696292. Update in: *J Thorac Cardiovasc Surg.* 2026 Mar 4:S0022-5223(26)00187-X. doi:10.1016/j.jtcvs.2026.02.030. PMID: 41509400; PMCID: PMC12776338.

Gorlova OY, Gorlov IP, Ripley RT, Cheng C, Li Y, Peng B, Liu Y, Jang HJ, Kang SW, Lee C, Ranchod P, Burt BM, Lee HS, Amos CI. Exposure-inducible genes may contribute to missingness in RNAseq-based gene expression analyses. *Sci Rep.* 2025 Aug 22;15(1):30889. doi:10.1038/s41598-025-14395-0. PMID: 40846739; PMCID: PMC12373826.

Yeom K, Lee HS, Cho W, Sung JH, Kim KT. High-dynamic-range temporal characterization of laser pulses using tunneling ionization. *Opt Express.* 2026 Apr 20;34(8):14352-14361. doi:10.1364/OE.593456. PMID: 42071548.

Jang HJ, Patel M, Wang DY, Kang SW, Choi JM, Lee C, Vilchis M, Shim JS, Mitra S, Ranchod P, Kuncheria A, Hudson W, Jindra P, Lenge De Rosen V, Raminení M, Camp ER, Kheradmand F, Ripley RT, Groth SS, Lee HS, Burt BM. Ad-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma. *Clin Cancer Res.* 2025 Jul 1;31(13):2639-2654. doi:10.1158/1078-0432.CCR-24-4024. PMID: 40208070; PMCID: PMC12237568.

LOOR G

Nguyen A, Rana A, Shafii A, Loor G, Civitello A, Rosengart T, Liao K. Risk factors when considering heart transplants with donors aged 45 or above: Development of a Novel Mortality Risk Score using UNOS data. *JHLT Open.* 2026 Jan 23;12:100497. doi:10.1016/j.jhlto.2026.100497. PMID: 41716216; PMCID: PMC12914790.

Nguyen A, Rana A, Shafii A, Loor G, Civitello A, Rosengart T, Liao K. Novel model to predict survival in DCD heart transplants: Development of a mortality risk score using UNOS data. *JHLT Open.* 2026 Mar 3;12:100530. doi:10.1016/j.jhlto.2026.100530. PMID: 41908105; PMCID: PMC13019768.

Nguyen A, Shafii A, Loor G, Civitello A, Frazier OH, Rosengart T, Liao K. Driveline Infections Among Patients Supported With Left Ventricular Assist Devices: A Single Center Sixteen-Year Longitudinal Profile. *Artif Organs.* 2026 Apr;50(4):572-579. doi:10.1111/aor.70082. Epub 2025 Dec 21. PMID: 41423428; PMCID: PMC13125384.

Kashem MA, Loor G, Hartwig M, Van Raemdonck D, Villavicencio M, Ius F, Ghadimi K, Salman J, Chandrashekarán S, Machuca T, Sanchez PG, Subramaniam K, Neyrinck A, Calvelli H, Warnick M, Zhao H, Huddleston S, Osho A, D’Silva E, Ramamurthy U, Pena AL, Salan-Gomez M, Shaffer A, Langer N, Emtiazjoo A, Toyoda Y. Corrigendum to “A multi-center analysis of lung transplantation outcomes comparing donation after circulatory death and donation after brain death” [*JHLT Open* (2024) 100132]. *JHLT Open.* 2025 Nov 5;10:100431. doi:10.1016/j.jhlto.2025.100431. Erratum for:

JHLT Open. 2024 Jul 24;6:100132. doi:10.1016/j.jhlto.2024.100132. PMID: 41322121; PMCID: PMC12664580.

Han JW, Peer SB, Loor G, Shafii A, Díaz-Gómez JL. Perioperative Echocardiographic Management of a Surgical Right Pulmonary Artery-Left Atrial Shunt as a Bridge to Lung Transplantation. *CASE (Phila).* 2025 Apr 1;9(6):187-193. doi:10.1016/j.case.2025.02.003. PMID: 40583872; PMCID: PMC12198111.

Banday MM, Rahman M, Goda Y, Potter AS, Naito T, Mallidi H, Surolia R, Lee S, Rehman R, Loor G, Hayes D Jr, Sharma NS. Mechanistic analysis of an IRF7-dependent pathway in virus-induced fibrosis in chronic lung allograft dysfunction. *EBioMedicine.* 2026 May 8;128:106285. doi:10.1016/j.ebiom.2026.106285. Epub ahead of print. PMID: 42105629; PMCID: PMC13187531.

Goda Y, Lee S, Chawda A, Xu X, Khan MM, Do GV, Hills E, Pena AL, Lopez PDC, Gaggar A, Coppolino A, Hochman-Mendes C, Loor G, Banday MM, Sharma NS. Targeting the proline-glycine-proline-protease feed-forward loop attenuates primary graft dysfunction after lung transplantation. *Front Immunol.* 2026 Feb 20;17:1655536. doi:10.3389/fimmu.2026.1655536. PMID: 41798933; PMCID: PMC12963002.

Wisniewski AM, Suzuki Y, El Moheb M, Chipoletti A, Strobel RJ, Norman AV, Lynch W, Chatterjee S, Loor G, Teman NR, Carrott P. Cannulation Configuration and Its Effects on Bridging to Lung Transplant: Analysis of the Extracorporeal Life Support Organization Registry. *Ann Thorac Surg.* 2025 Aug;120(2):383-392. doi:10.1016/j.athoracsur.2024.12.011. Epub 2024 Dec 24. PMID: 39725254; PMCID: PMC12185772.

Nguyen A, Rana A, Shafii A, Loor G, Civitello A, Reyes JEM, Frazier OH, Rosengart T, Liao K. Potential intermediate-term survival differences among heart transplant recipients from circulatory death vs brain death donors. *JHLT Open.* 2025 Jul 10;9:100342. doi:10.1016/j.jhlto.2025.100342. PMID: 40756005; PMCID: PMC12318337.

Padhye AA, Guffey D, Leon-Pena A, Segraves J, Fernandez R 2nd, Loor G, Garcha P, Wu TD, Li G. Antithymocyte globulin therapy in chronic lung allograft dysfunction. *Front Transplant.* 2025 Jul 4;4:1607678. doi:10.3389/frtra.2025.1607678. PMID: 40687845; PMCID: PMC12271178.

Fernandez R, Ius F, Reyes JEM, de Manna ND, Leon-Pena A, Hartwig M, Ghadimi K, Langer NB, Osho AA, Kashem M, Toyoda Y, Emtiazjoo A, Rackauskas M, Ceulemans LJ, Vanluyten C, Huddleston S, Kathirvel S, Carrasco SC, Sanchez PG, Ramamurthy U, Van Raemdonck D, Loor G. Outcomes of central versus peripheral arterial cannulation for intraoperative extracorporeal membrane oxygenation support in lung transplantation. *J Heart Lung Transplant.* 2026 Feb;45(2):242-250. doi:10.1016/j.healun.2025.09.025. Epub 2025 Oct 8. PMID: 41072743.

Loor G, Warnecke G, Villavicencio MA, Smith MA, Zhou X, Kukreja J, Ardehali A, Hartwig MG, Daneshmand MA, Hertz MI, Huddleston SJ, Haverich A, Madsen JC, Neyrinck A, Van Raemdonck D. Long-term outcomes of the international EXPAND trial of Organ Care System (OCS) Lung preservation for lung transplantation. *EClinicalMedicine.* 2025 Jul 8;85:103334. doi:10.1016/j.eclim.2025.103334. PMID: 40686680; PMCID: PMC12273511.

MANIAN P

Munroe ES, Grandits GA, Hyzy RC, Prescott HC, Barrett TW, Dewar RL, Engen N, Goodman AL, Hatlen TJ, Highbarger H, Holland TL, Hughes G, Jensen TO, Khan MA, Kalomenidis I, Kang N, Laverdure S, Manian P, Menon V, Patel R, Ramachandruni S, Rehman T, Shaw-Saliba K, Røge BT, Vock DM, Weintrob AC, Young BE, Frosch AP; STRIVE Network and Therapeutics for Inpatients with COVID-19 (TICO) study groups. Long-term anti-SARS-CoV-2 antibody trajectories after neutralizing monoclonal antibody treatment. *PLoS One.* 2025 Jun 18;20(6):e0325561. doi:10.1371/journal.pone.0325561. PMID: 40531973; PMCID: PMC12176123.

Li P, Zhang Z, Monaco TA, Dong Y, Rong Y. Grazing Intensities Regulated the Effects of Seasonal Dietary Pattern on Gut Bacterial Community Composition of Sheep. *Microorganisms*. 2025 Jun 14;13(6):1392. doi:10.3390/microorganisms13061392. PMID: 40572278; PMCID: PMC12196464.

NAIR A

Nair A, van der Kaaij NP, Kluin J, Rogers J. Total artificial hearts: an evolution on the horizon. *Eur Heart J*. 2026 May 25;ehag395. doi:10.1093/eurheartj/ehag395. Epub ahead of print. PMID: 42183865.

Kherallah RY, Lamba HK, Civitello AB, Nair AP, Simpson L, Shafii AE, Loor G, George JK, Delgado RM, Liao KK, Stainback RF, Frazier OH, Koneru S. Effect of Preoperative Mitral Regurgitation on LVAD Outcomes in Patients with Elevated Pulmonary Vascular Resistance. *Cardiovasc Drugs Ther*. 2025 Oct;39(5):1085-1095. doi:10.1007/s10557-024-07581-1. Epub 2024 Aug 20. PMID: 39162770.

Byrne RD, Nair AP, Dolgner SJ, Choudhry S, Hickey EJ, Wood AC, Fedson S, Bozkurt B, Broda CR. Construct and Predictive Validity of the Kansas City Cardiomyopathy Questionnaire in Adult Congenital Heart Disease. *JACC Adv*. 2025 Aug;4(8):102020. doi:10.1016/j.jacadv.2025.102020. Epub 2025 Jul 24. PMID: 40712272; PMCID: PMC12311496.

Walther CP, Nair AP. Management of Dialysis for Patients Receiving Mechanical Circulatory Support. *J Am Soc Nephrol*. 2026 Mar 1;37(3):596-606. doi:10.1681/ASN.0000001013. Epub 2025 Dec 24. PMID: 41563801; PMCID: PMC12935348.

Walther CP, Lamba HK, Nair AP, Civitello AB, Mondal NK, Liao KK, Navaneethan SD. Kidney Function Trajectories With Mechanical Circulatory Support. *Kidney Int Rep*. 2025 Jul 29;10(10):3549-3563. doi:10.1016/j.ekir.2025.07.034. PMID: 41141536; PMCID: PMC12546638.

Wang A, Garcia-Pavia P, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett BL, Costabel JP, de Barros Correia E, Dybro A, Elliott P, Hegde SM, Kulac IJ, Lakdawala NK, Lewis GD, Mann A, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Maron MS; MAPLE-HCM Investigators. Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. *J Am Coll Cardiol*. 2026 Mar 3;87(8):1029-1042. doi:10.1016/j.jacc.2025.10.057. Epub 2025 Nov 18. PMID: 41348072.

Nassif ME, Garcia-Pavia P, Masri A, Merkely B, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett BL, Costabel JP, de Barros Correia E, Dybro AM, Elliott P, Lakdawala NK, Lewis GD, Mann A, Maron MS, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Spertus JA; MAPLE-HCM Investigators. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. *J Am Coll Cardiol*. 2026 Mar 3;87(8):1046-1058. doi:10.1016/j.jacc.2025.10.059. Epub 2025 Nov 18. PMID: 41493295.

Hegde SM, Wang X, Garcia-Pavia P, Getchevski S, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Lakdawala NK, Mann A, Maron MS, Nair A, Poulsen SH, Reant P, Schulze PC, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Solomon SD; MAPLE-HCM Investigators. Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM. *J Am Coll Cardiol*. 2025 Dec 16;86(24):2452-2467. doi:10.1016/j.jacc.2025.08.022. Epub 2025 Aug 27. PMID: 40932433.

Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Hegde SM, Lakdawala NK, Lewis GD, Mann A, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA; MAPLE-HCM Investigators. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. *N Engl J Med*. 2025 Sep 11;393(10):949-960. doi:10.1056/NEJMoa2504654. Epub 2025 Aug 30. PMID: 40888697.

Schuman AD, Ongkasuwan J. National trends in pediatric laryngeal reinnervation. *Int J Pediatr Otorhinolaryngol*. 2025 Aug;195:112443. doi:10.1016/j.ijporl.2025.112443. Epub 2025 Jun 20. PMID: 40561875.

Schuman AD, Narayana V, Ongkasuwan J. Type 1 Thyroplasty for Chronic Cough. *J Voice*. 2026 Mar;40(2):511-513. doi:10.1016/j.jvoice.2023.10.034. Epub 2023 Nov 15. PMID: 37977966.

Buell JB, Schuman AD, Ongkasuwan J, Szymanowski A. Hypopharyngeal Amyloidosis: A Rare Cause of Dysphagia. *Laryngoscope*. 2025 Jun;135(6):2086-2088. doi:10.1002/lary.32021. Epub 2025 Feb 2. PMID: 39895196.

Schuman AD, Buell JB, Varghese V, Brungardt ME, Blumhardt SL, Ongkasuwan J, Szymanowski AR. A Comparison of Therapy Adherence for Vocal Fold Atrophy and Chronic Cough. *Laryngoscope*. 2025 Jun;135(6):2076-2080. doi:10.1002/lary.31971. Epub 2025 Jan 19. PMID: 39829086.

Abarca L, Arya P, Singer A, Ongkasuwan J, Szymanowski AR. Treatment of Dysphonia in Patients with Parkinson’s Disease: A Scoping Review. *J Voice*. 2026 Apr 14:S0892-1997(26)00131-1. doi:10.1016/j.jvoice.2026.03.019. Epub ahead of print. PMID: 41986189.

Joshi A, Awan SN, Rubino M, Devore D, Procter T, Ongkasuwan J. Cepstral Peak Prominence in Nondysphonic Children Using Praat and Analysis of Dysphonia in Speech and Voice. *J Speech Lang Hear Res*. 2025 Aug 12;68(8):3733-3747. doi:10.1044/2025_JSLHR-25-00046. Epub 2025 Jul 2. PMID: 40601663.

POLVERINO F

Kaes J, Hooft C, Jin X, Heigl T, Liu H, Pollenus E, Prenen F, Beckmans H, Kerckhof P, Vanstapel A, Van Slambrouck J, Mercurio M, Zapata-Ortega M, Aerts G, Geudens V, Vermaut A, Vanvuchelen L, Somers A, Verbeylen L, Vanluyten C, Barbarossa A, Mohamady Y, Özsoy B, Zajacova A, Tielemans B, Yildirim AO, Bos S, De Sadeleer L, Godinas L, Rojas Quintero J, Polverino F, Van den Steen PE, Ceulemans LJ, Vos R, Vanaudenaerde BM. Blood vessels as primary site of rejection in murine lung transplantation. *Transpl Int*. 2026;39:16293.

Zhang Y, Wei H, Nouws J, Jiang W, Brewster RM, Nguyen JP, Liang S, Pass SM, Wang W, Collin F, Oill AT, Kim SH, Siller SS, Liu J, Zhao AY, Hansbro P, Dela Cruz C, Britto C, Gomez J, Cloonan SM, Herzog EL, Lam TT, Banovich NE, Raredon MSB, Zhang X, Mangiola S, Homer RJ, Kaminski N, McDonough J, Polverino F, Yan X, Sauler M. Aberrant cellular communities underlying disease heterogeneity in chronic obstructive pulmonary disease. *Nat Genet*. 2026;58(2):376-391.

Idrees S, Chen H, Sadaf T, Rehman SF, Johansen MD, Paudel KR, Liu G, Wang Y, Luecken MD, Hortle E, Philp AS, Budden KF, O’Rourke M, Kaiko GE, Lucas SEM, Dickinson JL, Allen PC, Powell JE, Zhang LY, Chambers DC, Corte T, Caramori G, Sauler M, Wark PA, Gote-Schniering J, Lehmann M, Conlon TM, Kapellos TS, Yildirim AÖ, Faner R, Dharmage SC, Wheelock CE, van den Berge M, Nawijn MC, Polverino F, Belz GT, Chotirmall SH, Segal LN, Faiz A, Hansbro PM. Multi-omics to study chronic respiratory diseases and viral infections. *Eur Respir Rev*. 2026;35(179):240286. Review.

Ito A, Kang SW, Jang HJ, Shim JS, Lee C, Ranchod P, Lee G, Mitra S, Jeon J, Syarif AH, Zhang Y, Byun J, Han Y, Malo J, Patel M, Ripley RT, Groth SS, Kheradmand F, Polverino F, Amos CI, Lee HS. Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer. *bioRxiv*. 2026. Preprint.

Polverino F, Borgaonkar R, Cong C, Sanz-Rubio D, Waich A, Wang W, Mettler S, Malo J, Rojas-Quintero J, Diaz AA. Mucus plugs on CT and small airway pathology in COPD. *ERJ Open Res*. 2025;11(6):00546-2025.

Granato E, Cerqua I, Rossi A, Riemma MA, Monti MC, Ferraro G, Romano B, Nani MF, D’Avino D, Simonelli M, Malo J, Polverino F, D’Agostino B, Cirino G, Roviezzo F. Sex hormones influence ORMDL3 expression: Implications for sex-associated asthma phenotype. *J Allergy Clin Immunol*. 2026;157(3):602-615.e7.

Zhang Y, Sauler M, Corry DB, Ochsner SA, Perusich S, Song LZ, Malo J, Estepar RSJ, Polverino F, Kheradmand F. Lung NR3C1+ and CXCR6high T cells distinguish immunopathogenesis of human emphysema. *Commun Biol*. 2025;8(1):1353.

Zhu Y, Gamare S, Polverino F, Owen CA, Somanath PR, Wang X, Zhang D. CYP1B1 Mediates Cigarette Smoke-Induced Lipid Accumulation in Alveolar Type 2 Cells. *FASEB J*. 2025;39(18):e71062.

Polverino F, Sin DD. The Developmental Origins of Asthma and COPD. *Annu Rev Physiol*. 2026;88:513-535. Review.

Rosas IO, McDowell-Sanchez AK, Sanchez S, Cala-Garcia JD, Cohen ARW, Echartea MER, Ochsner SA, Kraushaar D, Celada LJ, Sun D, Polverino F, Coarfa C, McKenna NJ, Tsoyi K. Macropinocytosis inhibition attenuates pro-fibrotic responses in lung fibroblasts and pulmonary fibrosis. *bioRxiv*. 2025. Preprint.

Bordag N, Jandl K, Syarif AH, Gindlhuber J, Schnoegl D, Mutgan AC, Foris V, Hoetzenecker K, Boehm PM, Breyer-Kohansal R, Zeder K, Gorkiewicz G, Polverino F, Crnkovic S, Kwapiszewska G, Marsh LM. Machine learning assisted immune profiling of COPD identifies a unique emphysema subtype independent of GOLD stage. *iScience*. 2025;28(7):112966.

Soriano JB, Polverino F. Reply to Chaïbi and Tandjaoui-Lambiotte and to Young and Scott. *Am J Respir Crit Care Med*. 2025;211(12):2425.

Wells JM, Krishnan JA, Wade RC, Kinney G, Wise RA, Neptune E, Polverino F, Hanania NA, Moll M, Königshoff M, Chandra D, Sciruba F, Marchetti N, San José Estépar R, Diaz AA, El-Kersh K, Castro M, Zhang Y, Holbrook JT, Sugar EA, Kraft M, Kaner RJ, Make B, Rennard S. Post-COPD: Can Emphysema Be Repaired? *Am J Respir Crit Care Med*. 2025;211(9):1600-1609.

Moll M, Xu Z, Boueiz A, Ryu MH, Silverman EK, Cho MH, Hersh CP, Sauler M, Polverino F, Kinney GL, Curtis JL, Crotty-Alexander LE, Vollmers C, Castaldi PJ. B-cell immune repertoire sequencing in tobacco cigarette smoking, vaping, and chronic obstructive pulmonary disease in the COPDGene cohort. *Front Immunol*. 2025;16:1508786.

Polverino F. Beyond Obstruction—A Milestone in COPD Diagnosis. *JAMA*. 2025;333(24):2151-2153.

Soriano JB, Polverino F. The Resilience of the Human Lungs: Evolution, Smoke, and Disease. *Am J Respir Crit Care Med*. 2025;211(8):1343-1345.

Enzer NA, Chiles J, Mason S, Shirahata T, Castro V, Regan E, Choi B, Yuan NF, Diaz AA, Washko GR, McDonald ML, Estépar RSJ; COPDGene Study Consortium. Author Correction: Proteomics and machine learning in the prediction and explanation of low pectoralis muscle area. *Sci Rep*. 2025;15(1):7613.

Polverino F, Han MK. Eosinophils in COPD type 2 inflammation: hope or hype? *Eur Respir J*. 2025;65(5):2500194.

Rojas-Quintero J, Polverino F. Molecular Maestro in the Lung: The Sphingolipid Rheostat. *Am J Respir Cell Mol Biol*. 2025;73(2):170-172.

Rodríguez-Sanz J, Muñoz-González N, Cubero JP, Ordoñez P, Gil V, Langarita R, Ruiz M, Forner M, Marín-Oto M, Vera E, Baptista P, Polverino F, Domingo JA, García-Tirado J, Marin JM, Sanz-Rubio D. Peripheral Extracellular Vesicles for Diagnosis and Prognosis of Resectable Lung Cancer: The LUCEx Study Protocol. *J Clin Med*. 2025;14(2):411.

Liu G, Hsu AC, Geirnaert S, Cong C, Nair PM, Shen S, Marshall JE, Haw TJ, Fricker M, Philp AM, Hansbro NG, Pavlidis S, Guo Y, Burgess JK, Castellano L, Ieni A, Caramori G, Oliver BGG, Chung KF, Adcock IM, Knight DA, Polverino F, Bracke K, Wark PA, Hansbro PM. Vitronectin regulates lung tissue remodeling and emphysema in chronic obstructive pulmonary disease. *Mol Ther*. 2025;33(3):917-932.

Zhu Y, Dutta S, Han Y, Choi D, Polverino F, Owen CA, Somanath PR, Wang X, Zhang D. Oxidative stress promotes lipid-laden macrophage formation via CYP1B1. *Redox Biol*. 2025;79:103481.

Summers B, Kim K, Trivedi A, Lu TM, Houghton S, Palmer-Johnson J, Rojas-Quintero J, Cala-Garcia J, Pannellini T, Polverino F, Lis R, Reed HO. Mice with lymphatic dysfunction develop pathogenic lung tertiary lymphoid organs that model an autoimmune emphysema phenotype of COPD. *Am J Physiol Lung Cell Mol Physiol*. 2025;328(1):L1-L14.

24. Rojas-Quintero J, Ochsner SA, Lee HS, Cong C, Waich Cohen A, Colborg AS, Tsoyi K, Basil MC, Cantu E, Rosas IO, McKenna NJ, San-José Estépar R, Barjaktarevic I, Wilson AA, Polverino F. Skewed adaptive immune responses are involved in alpha-1 antitrypsin deficiency emphysema. *Eur Respir J*. 2025;65(1):2400839.

ROSAS IO

Podolanczuk AJ, Hunninghake GM, Wilson KC, Khor YH, Kheir F, Pang B, Adegunsoye A, Cararie G, Corte TJ, Flanagan J, Gudmundsson G, Hariri LP, Hatabu H, Humphries SM, Kaul B, Kim JS, Königshoff M, Kropski JA, Lee JS, Luo F, Lynch DA, Martinez FJ, Montesi SB, Moodley Y, Oldham JM, Piciucchi S, Putman RK, Richeldi L, Rosas IO, Salisbury ML, Salvatore MM, Selman M, Seo JB, Song JW, Thomson CC, Vivero M, Wain LV, Wijsenbeek M, Schwartz DA, Ryerson CJ. Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement. *Am J Respir Crit Care Med*. 2025 Jul;211(7):1132-1155. doi:10.1164/rccm.202505-1054ST. Erratum in: *Am J Respir Crit Care Med*. 2025 Sep;211(9):1727. doi:10.1164/rccm.v211erratum4. PMID: 40387336; PMCID: PMC12264694.

Wagner DE, Alsafadi HN, Mitash N, Justet A, Hu Q, Pineda R, Staab-Weijnitz C, Korfei M, Gvazava N, Wannemo K, Onwuka U, Mozurak M, Estrada-Bernal A, Cala-Garcia J, Mutze K, Costa R, Bölikbas D, Stegmayr J, Skronska-Wasek W, Klee S, Ota C, Baarsma HA, Wang J, Sembrat J, Hilgendorff A, Ding J, Günther A, Chambers R, Rosas I, de Langhe S, Kaminski N, Lehmann M, Eickelberg O, Königshoff M. Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models. *Nat Commun*. 2025 Aug 2;16(1):7099. doi:10.1038/s41467-025-61795-x. PMID: 40753090; PMCID: PMC12318044.

Adams TS, Schupp JC, Balayev A, Khoury J, Justet A, Nikola F, De Sadeleer LJ, Cala-Garcia J, Zapata-Ortega M, Benos PV, McDonough JE, Ahangari F, Königshoff M, Ding J, Homer RJ, Rosas I, Yan X, Vanaudenaerde BM, Wuyts WA, Kaminski N. Alveolar epithelial cell plasticity and injury memory in human pulmonary fibrosis. *bioRxiv* [Preprint]. 2025 Jun 21:2025.06.10.658504. doi:10.1101/2025.06.10.658504. PMID: 40667263; PMCID: PMC12262340.

Liu H, Coarfa C, Charania AN, Larson-Casey JL, Rosas IO, He C. Secreted Phosphoprotein 1 in Lung Diseases. *Metabolites*. 2025 May 30;15(6):365. doi:10.3390/metabo15060365. PMID: 40559389; PMCID: PMC12195332.

Zheng Y, Schupp JC, Adams T, Clair G, Justet A, Ahangari F, Yan X, Hansen P, Carlon M, Cortesi E, Vermant M, Vos R, De Sadeleer LJ, Rosas IO, Pineda R, Sembrat J, Königshoff M, McDonough JE, Vanaudenaerde BM, Wuyts WA, Kaminski N, Ding J. A deep generative model for deciphering cellular dynamics and in silico drug discovery in complex diseases. *Nat Biomed Eng*. 2025 Dec;9(12):2155-2180. doi:10.1038/s41551-025-01423-7. Epub 2025 Jun 20. PMID: 40542107; PMCID: PMC12705450.

Casanova NG, Herazo-Maya JD, Kempf CL, Sun BL, Song JH, Hernandez A, Canizales Galaviz J, Sun X, Camp SM, Ledford JG, Hellinger RD, Rodriguez M, Zhao AY, Unterman A, Rosas I, Duncan S, Thannikal VJ, Hufford MK, Ahmed M, Zaghoul N, Gupta A, Bime C, Sammani S, Stansfield BN, Chen J, Anandhan A, Disney MD, Ooi A, Kee SL, Karampitsakos T, Benos PV, Kaminski N, Zhang D, Garcia JGN. eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis. *Am J Respir Cell Mol Biol*. 2025 Oct;73(4):572-585. doi:10.1165/rcmb.2024-0342OC. PMID: 40126452; PMCID: PMC12498369.

Putman RK, Rose JA, San José Estepar R, Tukpah AC, Cutting CC, Hino T, Hata A, Nishino M, Humphries SM, Lynch DA, Silverman EK, Cho MH, Rosas IO, Washko GR, Hatabu H, San José Estepar R, Hunninghake GM. Visual and Quantitative Interstitial Lung Abnormality Progression in COPDGene. *Am J Respir Crit Care Med*. 2025 Oct;211(10):1794-1801. doi:10.1164/rccm.202501-0247OC. PMID: 40720797; PMCID: PMC12555042.

Peng F, Jiang CS, Zheng Z, Aliyari S, Shan D, Sabharwal A, Yin Q, Saito S, He C, Rosas IO, Lasky JA, Thannickal VJ, Zhou Y. Transcriptomic signature-guided depletion of intermediate alveolar epithelial cells ameliorates pulmonary fibrosis in mice. Nat Commun. 2026 Jan 10;17(1):1636. doi:10.1038/s41467-026-68354-y. PMID: 41519994; PMCID: PMC12905394.

Rosas IO, McDowell-Sanchez AK, Sanchez S, Cala-Garcia JD, Cohen ARW, Echartea MER, Ochsner SA, Kraushaar D, Celada LJ, Sun D, Polverino F, Coarfa C, McKenna NJ, Tsoyi K. Macropinocytosis inhibition attenuates pro-fibrotic responses in lung fibroblasts and pulmonary fibrosis. bioRxiv [Preprint]. 2025 Jul 14:2025.07.09.663937. doi:10.1101/2025.07.09.663937. Update in: J Clin Invest. 2026 Apr 30:e197651. doi:10.1172/JCI197651. PMID: 40791420; PMCID: PMC12338576.

De Man R, McDonough JE, Adams TS, Nikola F, Rangel R, Anderson S, Manning EP, Cala Garcia J, Moss B, Waich A, Poli F, Cardenas R, Coarfa C, Song Q, Bar-Joseph Z, Vanaudenaerde BM, Wuyts WA, Niklason L, Raredon MSB, Yan X, Rosas IO, Kaminski N. Single-cell atlas of human lung aging identifies cell type dyssynchrony and increased transcriptional entropy. Nat Commun. 2026 Jan 22;17(1):2095. doi:10.1038/s41467-026-68810-9. PMID: 41571679; PMCID: PMC12953888.

Liu H, Xia C, Zhang Y, Gan Y, Cheng L, Wang X, Chang A, Zhao W, Li B, Wang Y, Li Y, Rosas I, Yang J, Yu G, Wang L. PTPN1 Regulation via YBX1-PTBP1 Interaction Promotes Fibroblast Activation and Fibrotic Remodeling in the Lung. Int J Biol Sci. 2026 Jan 30;22(5):2233-2246. doi:10.7150/ijbs.123875. PMID: 41800249; PMCID: PMC12965075.

Rose JA, Steele MP, Kosak Lopez EJ, Axelsson GT, Galecio Chao AG, Waich A, Regan K, Gulati S, Maeda AH, Sultana S, Cutting C, Tukpah AC, Synn AJ, Rice MB, Goldberg HJ, Lee JS, Lynch DA, Putman RK, Hatabu H, Raby BA, Schwartz DA, Rosas IO, Hunninghake GM. Protein biomarkers of interstitial lung abnormalities in relatives of patients with pulmonary fibrosis. Eur Respir J. 2025 Jun 5;65(6):2401349. doi:10.1183/13993003.01349-2024. PMID: 39884764; PMCID: PMC12138028.

Mao H, Li CM, Sun B, Ward CS, Waich-Cohen AR, Rosas IO, Huang HJ, Karmouty-Quintana H, Xie L, Pandit LM, Pi X. Inhibition of BMPER Mitigates Pulmonary Hypertension by Modulating LRP1-YAP Interaction in Smooth Muscle Cells. Arterioscler Thromb Vasc Biol. 2025 Nov;45(11):2037-2052. doi:10.1161/ATVBAHA.124.322189. Epub 2025 Sep 18. PMID: 40964716; PMCID: PMC12812256.

Rosas IO, Benitez A, McKinnell JA, Shah R, Waters M, Hunter BD, Jeanfreau R, Tsai L, Neighbors M, Trzaskoma B, de Cassia Castro R, Cai F. Long-Term Clinical Outcomes of Adults Hospitalized for COVID-19 Pneumonia. Emerg Infect Dis. 2025 Jun;31(6):1158-1168. doi:10.3201/eid3106.241097. PMID: 40439451; PMCID: PMC12123926.

McKenna NJ, Ochsner SA, Waich A, Cala-Garcia J, Echartrea MER, Grimm S, Poli F, Castillo RC, Zuluaga JD, Poli S, Adams TS, Pineda R, Moss B, Ryter SW, Pillich RT, Villalba JA, Kato K, Hecker L, Celada LJ, Sauler M, Koenigshoff M, Kaminski N, Raby B, Agarwal S, Tsoyi K, Coarfa C, Rosas IO. Single cell transcriptomics in a treatment-segregated cohort exposes a STAT3-regulated therapeutic gap in idiopathic pulmonary fibrosis. bioRxiv [Preprint]. 2025 Jun 21:2025.06.16.659944. doi:10.1101/2025.06.16.659944. PMID: 40666833; PMCID: PMC12262394.

Khanna D, Spino C, Tashkin DP, Bernstein EJ, Goldin J, Kleerup EC, Harui A, Ibrahim G, Kim GHJ, Huang S, McLain R, Tu YH, Nagaraja V, Silver RM, Steen VD, Weigt SS, Lee JS, Fischer A, Scholand MB, Gordon JK, Dellaripa PF, Rosas IO, Hunninghake GM, Trojanowski MA, Simms RW, Dematte JE, Hsu VM, Domsic RT, Raghu G, Mayes MD, Boente RD, Roth MD; Scleroderma Lung Study III Investigators. Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. ACR Open Rheumatol. 2025 Dec;7(12):e70126. doi:10.1002/acr2.70126. PMID: 41294296; PMCID: PMC12648624.

Goda Y, Naito T, Banday MM, Potter AS, Odintsov I, Patel K, Davis N, Lee S, Gaggar A, Rosas I, Loor G, Hayes D Jr, Sharma NS. Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in chronic lung allograft dysfunction. J Heart Lung Transplant. 2026 Jun;45(6):1008-1012. doi:10.1016/j.healun.2026.01.028. Epub 2026 Feb 7. PMID: 41663041.

Rosas IO, McDowell-Sanchez AK, Sanchez S, Cala-Garcia JD, Waich Cohen AR, Ruiz-Echartea E, Ochsner SA, Kraushaar DC, Celada LJ, Sun D, Polverino F, Coarfa C, McKenna NJ, Tsoyi K. Macropinocytosis inhibition attenuates pro-fibrotic responses in lung fibroblasts and pulmonary fibrosis models. J Clin Invest. 2026 Apr 30:e197651. doi:10.1172/JCI197651. Epub ahead of print. PMID: 42066052.

Ni W, Schwartz DA, Synn AJ, Fernandez-Wever ML, Lopez EJK, Galecio Chao AG, Waich A, Gulati S, Putman R, Lynch DA, Raby B, Rosas IO, Hunninghake GM, Steele MP, Rice MB. Occupational inhaled exposures and risk of interstitial lung abnormalities in individuals with potential familial susceptibility to pulmonary fibrosis. Thorax. 2026 May 4:thorax-2025-224109. doi:10.1136/thorax-2025-224109. Epub ahead of print. PMID: 42082357.

SAFI J

Eltahir M, Safi J, Wang BG. Cytologic Diagnosis of Lymphomatoid Granulomatosis, A Case Report and Review of the Literature. Diagn Cytopathol. 2025 Jul;53(7):E127-E132. doi:10.1002/dc.25475. Epub 2025 Apr 11. PMID: 40214114.

SHARMA N

Cable J, Giuli R, Fox MR, Rosen RL, Valdovinos-García LR, Siboni S, Clarke JO, Johnston N, Samuels TL, Scarpignato C, Stein EM, Fass R, Remes-Troche JM, Khan A, Rahman AK, Lynch K, Jodorkovsky D, Vela MF, Vandenberg A, Kuo B, Ergun P, Jirapinyo P, Asti E, Tolone S, Sheu EG, Salvador R, Sozzi M, Husain IA, Wu JC, Hobson A, Sharma NS, Lo WK, Duncan DR, Gyawali CP, Chan WW, Siffrim D, Savarino E, de Bortoli N, Rogers BD. Gatherings in Esophagology: Innovations and Future Directions in the Diagnosis and Management of Reflux Disease. Ann N Y Acad Sci. 2026 Mar;1557(1):e70225. doi:10.1111/nyas.70225. Erratum in: Ann N Y Acad Sci. 2026 Apr;1558(1):e70279. doi:10.1111/nyas.70279. PMID: 41817458; PMCID: PMC12981296.

Grobman B, Courtwright AM, Yeung M, Jacob S, Lee S, Sheikh A, Keshk M, Hackman A, Coppolino A, Dunning J, Sharma N, Goldberg HJ. Long-Term Chronic Lung Allograft Dysfunction-Free Survival Following Lung Transplant in the Presence of Donor-Specific Antibodies. Clin Transplant. 2025 Aug;39(8):e70241. doi:10.1111/ctr.70241. PMID: 40698562; PMCID: PMC12313243.

Banday MM, Banday S, Rahman M, Harrison AO, Singh N, Moore RM, Khan MM, Shankar S, Goda Y, Coppolino A, Movval N, Stutts S, Woolley A, Dishaw L, Goldberg H, Mebratu Y, Polson SW, Patel KN, Gaggar A, Hayes D Jr, Krishnamoorthy N, Gewurz BE, Washko G, Tesfaigzi Y, Rehman R, Sharma NS. Anellovirus-Mediated Interferon Dysregulation Enhances Virus-Induced Lung Injury. Am J Respir Cell Mol Biol. 2026 Mar 15:aanag048. doi:10.1093/ajrcmb/aanag048. Epub ahead of print. PMID: 42089290.

Heyman A, Punko D, Meyer F, Keller BC, Langer N, Sharma N, Coppolino A, Restrepo J. The Use of Opioid Medications in Lung Transplant: A Scoping Review. Transplantation. 2025 Aug 1;109(8):1340-1349. doi:10.1097/TP.0000000000005343. Epub 2025 Mar 25. PMID: 40128171.

Goda Y, Sharma NS, Potter AS, Hayes D Jr. Airway epithelial cell chimerism and chronic lung allograft dysfunction associated with ischemia-reperfusion-injury in lung transplantation. Curr Opin Organ Transplant. 2025 Oct 1;30(5):365-371. doi:10.1097/MOT.0000000000001238. Epub 2025 Jul 7. PMID: 40620157.

Olanipekun T, Divo M, Abe T, Taddesse A, Poli S, Jacob S, Sheikh A, Sharma N. Respiratory oscillometry in monitoring lung transplant allograft function: a systematic scoping review. Eur Respir Rev. 2026 Jan 14;35(179):250018. doi:10.1183/16000617.0018-2025. PMID: 41534887; PMCID: PMC12801049.

Potter AS, Sharma NS, Goda Y, Patel KN, Qureshi MR, Halloran K, Halloran PF, Wallace C, Ashfaq A, Morales DLS, Hayes D Jr. Human lung allografts experience persistent fibrogenic shift following acute cellular rejection. J Heart Lung Transplant. 2026 Feb 23:S1053-2498(26)01724-9. doi:10.1016/j.healun.2026.02.1666. Epub ahead of print. PMID: 41740941.

Coppolino A, Maurer R, Woehl E, Connolly EM, Chamberlin E, Goldberg HJ, Jacob SS, Lee SF, Kennedy JC, Sheikh A, O’Neill AJ, Gupta S, Hernandez Acosta RA, Kovac V, Keshk M, Hackmann A, Dunning J, Sharma NS, Baden LR, Woolley AE. Bronchial stenosis after lung transplant: Risk factors and clinical outcomes. JHLT Open. 2025 Oct 4;11:100392. doi:10.1016/j.jhlto.2025.100392. PMID: 41624210; PMCID: PMC12857399.

Goda Y, Naito T, Banday MM, Potter AS, Odintsov I, Patel K, Davis N, Lee S, Gaggar A, Rosas I, Loor G, Hayes D Jr, Sharma NS. Spatial transcriptomics reveals coordinated endothelial and epithelial activator protein-1 activation in chronic lung allograft dysfunction. J Heart Lung Transplant. 2026 Jun;45(6):1008-1012. doi:10.1016/j.healun.2026.01.028. Epub 2026 Feb 7. PMID: 41663041.

Lo WK, Fernandez AM, Feldman N, Sharma N, Goldberg HJ, Chan WW. Increased reflux burden on pre-transplant reflux testing independently predicts significant pulmonary function decline after lung transplantation. World J Transplant. 2025 Sep 18;15(3):100111. doi:10.5500/wjt.v15.i3.100111. PMID: 40881742; PMCID: PMC12038592.

Goda Y, Lee S, Chawda A, Xu X, Khan MM, Do GV, Hills E, Pena AL, Lopez PDC, Gaggar A, Coppolino A, Hochman-Mendes C, Loor G, Banday MM, Sharma NS. Targeting the proline-glycine-proline-protease feed-forward loop attenuates primary graft dysfunction after lung transplantation. Front Immunol. 2026 Feb 20;17:1655536. doi:10.3389/fimmu.2026.1655536. PMID: 41798933; PMCID: PMC12963002.

Lo WK, Nadella P, Feldman N, Sharma N, Goldberg HJ, Chan WW. Increase in failed swallows from pre- to post-lung transplant esophageal function testing is associated with acute rejection. World J Transplant. 2025 Dec 18;15(4):107149. doi:10.5500/wjt.v15.i4.107149. PMID: 41357378; PMCID: PMC12679242.

Banday MM, Rahman M, Goda Y, Potter AS, Naito T, Mallidi H, Surolia R, Lee S, Rehman R, Loor G, Hayes D Jr, Sharma NS. Mechanistic analysis of an IRF7-dependent pathway in virus-induced fibrosis in chronic lung allograft dysfunction. EBioMedicine. 2026 May 8;128:106285. doi:10.1016/j.ebiom.2026.106285. Epub ahead of print. PMID: 42105629; PMCID: PMC13187531.

Keller BC, Agbor-Enoh S, Keller MB, Nandavaram S, Zeevi A, McDyer JF, Hays SR, Samuel Weigt S, Belperio JA, Sayah DM, Aryal S, Orens JB, Trindade AJ, Shaver CM, Yeung JC, Keshavjee S, Martinu T, Crespo MM, Christie JD, Diamond JM, Arcasoy SM, Tomic R, Sanchez PG, Byers DE, Palmer SM, Halloran K, Gray AL, Dilling DF, Natalini JG, Gries CJ, Budev MM, Sharma NS, Ross DJ, Bhorade S, Berry GJ, Khush KK, Woodward RN, Gray JN, Ensor CR, Levine DJ. Utility of donor-derived cell-free DNA testing after lung transplantation in the precision medicine era. J Heart Lung Transplant. 2026 Apr 15:S1053-2498(26)01837-1. doi:10.1016/j.healun.2026.04.005. Epub ahead of print. PMID: 41991095.

SIDANI, MOHAMAD

Guadarrama A, Mouw T, Onkendi EO, Sidani M, Das K, Brandi L. Multifocal Biliary Adenoma Involving the Gallbladder and Common Bile Duct Presenting With Obstructive Jaundice: A Case Report. Cureus. 2025 Sep 29;17(9):e93487. doi:10.7759/cureus.93487. PMID: 41170241; PMCID: PMC12571022.

SIDDIQUE, MUHAMMAD

Ch IA, Nasir K, Majeed U, Chaudhry A, Abdullah M, Haider A, Jamal A, Hussain A, Iftikhar H, Khalid S, Wu PT, Shah Y, Niaz A, Siddique M, Tahirkheli N. Effect of Statin Intensity on Cardiovascular Outcomes and Survival Following Coronary Artery Bypass Grafting. Clin Cardiol. 2025 Jul;48(7):e70170. doi:10.1002/clc.70170. PMID: 40590628; PMCID: PMC12210389.

Tsiachristas A, Chan K, Wahome E, Kearns B, Patel P, Lyasheva M, Syed N, Fry S, Halborg T, West H, Nicol E, Adlam D, Modi B, Kardos A, Greenwood JP, Sabharwal N, De Maria GL, Munir S, McAlindon E, Sohan Y, Tomlins P, Siddique M, Shirodaria C, Blankstein R, Desai M, Neubauer S, Channon

KM, Deanfield J, Akehurst R, Antoniadès C; ORFAN Consortium. Cost-effectiveness of a novel AI technology to quantify coronary inflammation and cardiovascular risk in patients undergoing routine coronary computed tomography angiography. Eur Heart J Qual Care Clin Outcomes. 2025 Jun 23;11(4):434-444. doi:10.1093/ehjqcco/qcae085. PMID: 39341792; PMCID: PMC12187117.

Oikonomou EK, Chan K, Patel P, Wahome E, Dangas K, Desai R, Sobirov I, Khera R, Petersen SE, Pugliese F, Rajani R, Nicol E, Kardos A, Adlam D, Kelion AD, Sabharwal N, Screation N, Greenwood JP, Rodrigues J, Huck D, Shirodaria C, Tomlins P, Siddique M, Sohan Y, Fry S, van Assen M, Blankstein R, Desai MY, Neubauer S, Channon KM, Deanfield J, Antoniadès C; ORFAN Consortium. Early Prediction of Heart Failure From Routine Cardiac CT Using Radiomic Phenotyping of Epicardial Fat. J Am Coll Cardiol. 2026 Apr 1:S0735-1097(26)05652-4. doi:10.1016/j.jacc.2026.02.5116. Epub ahead of print. PMID: 41949519.

SIDDIQUI, ZAID

Tavakoli M, Wadi-Ramahi S, Ashmeg S, Lalonde R, Siddiqui Z. Tumor-driven SRS VMAT planning: Regression models for intermediate and low dose spillage. J Appl Clin Med Phys. 2025 Aug;26(8):e70184. doi:10.1002/acm2.70184. PMID: 40744900; PMCID: PMC12313394.

Han Y, Hanania AN, Siddiqui ZA, Ugarte V, Zhou B, Mohamed ASR, Pathak P, Hamstra DA, Sun B. Simulation-free spine palliative radiotherapy enabled by AI-adapted diagnostic CT. Med Phys. 2026 Mar;53(3):e70366. doi:10.1002/mp.70366. PMID: 41746191; PMCID: PMC12940461.

Han Y, Pathak P, Awad O, Mohamed ASR, Ugarte V, Zhou B, Hamstra DA, Echeverria AE, Mekdash HA, Siddiqui ZA, Sun B. Optimizing and evaluating robustness of AI for brain metastasis detection and segmentation via loss functions and multi-dataset training. Biomed Phys Eng Express. 2026 Jan 6;12(1). doi:10.1088/2057-1976/ac308a. PMID: 41435436.

Rizwan A, Sherwani Y, Siddiqui Z, Farooqi H, Panda BP, Ansari MA, Khanday A. Epigenetic Inhibition of HDAC7 by Daidzein isolated from Macrotyloma uniflorum: A potential therapeutic approach in leukemia in silico, in-vitro and in-vivo. Med Oncol. 2026 Jan 12;43(2):111. doi:10.1007/s12032-025-03199-x. PMID: 41524858.

SZYMANOWSKI, ADAM

Szymanowski AR. Dysphonia in Hospitalized Patients. Med Clin North Am. 2026 Jan;110(1):67-80. doi:10.1016/j.mcna.2025.05.010. Epub 2025 Jul 1. PMID: 41206204.

Buell JB, Schuman AD, Ongkasuwan J, Szymanowski A. Hypopharyngeal Amyloidosis: A Rare Cause of Dysphagia. Laryngoscope. 2025 Jun;135(6):2086-2088. doi:10.1002/lary.32021. Epub 2025 Feb 2. PMID: 39895196.

Reilly BT, Szymanowski A, Soliman AMS. Development of a Peroral Vocal Fold Injection Training System. J Voice. 2025 Sep 15:S0892-1997(25)00344-3. doi:10.1016/j.jvoice.2025.08.025. Epub ahead of print. PMID: 40957756.

Wenneker E, Doctor R, Schuman A, Szymanowski A, Wang R. Transoral Robotic-Assisted Removal of a Submucosal Pyriform Sinus Foreign Body. Laryngoscope. 2025 Dec;135(12):4651-4654. doi:10.1002/lary.32454. Epub 2025 Jul 28. PMID: 40717651; PMCID: PMC12706552.

SchumanAD, Buell JB, Varghese V, Brungardt ME, Blumhardt SL, Ongkasuwan J, Szymanowski AR. A Comparison of Therapy Adherence for Vocal Fold Atrophy and Chronic Cough. Laryngoscope. 2025 Jun;135(6):2076-2080. doi:10.1002/lary.31971. Epub 2025 Jan 19. PMID: 39829086.

Abarca L, Arya P, Singer A, Ongkasuwan J, Szymanowski AR. Treatment of Dysphonia in Patients with Parkinson’s Disease: A Scoping Review. J Voice. 2026 Apr 14:S0892-1997(26)00131-1. doi:10.1016/j.jvoice.2026.03.019. Epub ahead of print. PMID: 41986189.

VAHDATPOUR, CYRUS

Vahdatpour C, Virk S, Ding H, Epstein S, Jones K, Alneser O, Albanna M, Eagan C, Fu K, Ossunuga O, Zaineddine L, Annis JS, Ebrahimi E, Ataya A, Kalra S, Brittain EL, Lowery MM, Hadigal S, Esser KA, Huo Z, Bryant AJ. Morning Larks and Night Owls: Considering Chronotype in Evaluation of Patients with Pulmonary Hypertension. *Ann Am Thorac Soc*. 2026 Feb 1;23(2):261-271. doi:10.1513/AnnalsATS.202502-190OC. PMID: 40929648; PMCID: PMC12983450.

Vahdatpour C, Clapham K, Kawut SM, Jones K Jr, Ryan JJ, Petty D, Talbot S, Dumoff K, Keeley EC, Lal P, Bryant AJ, Parker AM, Mazurek JA, Mirson L, Murphy A, Baird A, Schwietert M, Schurr A, Stein A, Hansen SM, Ou Z, Presson AP, Miller D. The right kind of rarefaction: Coronary microvascular remodeling in right ventricle failure. *JHLT Open*. 2025 Dec 2;11:100459. doi:10.1016/j.jhlto.2025.100459. PMID: 41568021; PMCID: PMC12816859.

WINOCOUR, SEBASTIAN

Vernik D, Payne C, Sinha K, Martinez C, Jungbauer WN, Jeger JL, Bohl M, Ropper AE, Winocour S, Reece E. Spinoplastic Surgery: A Review of Techniques, Indications, and Optimal Patient Selection. *Brain Sci*. 2025 Jun 30;15(7):705. doi:10.3390/brainsci15070705. PMID: 40722298; PMCID: PMC12293681.

Hancock M, Skochdopole AJ, Trevino M, Orozco-Sevilla V, Ripley RT, Winocour SJ. Intrathoracic breast implants for postpneumonectomy syndrome: A systematic review of safety and efficacy. *J Plast Reconstr Aesthet Surg*. 2026 Apr;115:33-46. doi:10.1016/j.bjps.2026.01.028. Epub 2026 Jan 30. PMID: 41722473.

Jungbauer WN Jr, Kalani M, Vernik D, Buchanan D, Unadkat K, Jeger JL, Van Spronsen N, Meyer J, Bohl M, Winocour S, Ropper AE, Reece E. Spinoplastic surgical intervention for the treatment of complex spinal disorders and cancer: An initial cohort of 30 vascularized bone grafts. *J Plast Reconstr Aesthet Surg*. 2026 May;116:158-164. doi:10.1016/j.bjps.2026.03.004. Epub 2026 Mar 7. PMID: 41962445.

ZOOROB, ROGER

Kim-Vences SIH, Zoorob RJ, Hirth JM. Lower Educational Attainment Widens Racial/Ethnic Disparities in Alcohol Use Disorder. *J Stud Alcohol Drugs*. 2025 Nov;86(6):939-946. doi:10.15288/jsad.24-00377. Epub 2025 Feb 14. PMID: 39951124; PMCID: PMC12576941.

Laytner LA, Chen P, Trautner BW, Nash S, Collazo A, Faustinella F, Olmeda K, Mancera A, Zoorob R, Paasche-Orlow MK, Grigoryan L. ‘Antibiotics are like gold’: a qualitative study of patient perspectives on the use of antibiotics without a prescription. *BMJ Public Health*. 2025 Jun 3;3(1):e002421. doi:10.1136/bmjph-2024-002421. PMID: 40521333; PMCID: PMC12164297.

Valentine-King M, Trautner BW, Hansen MA, Zoorob R, Danek LCK, Muldrew K, Hudson F, Atmar RL, Grigoryan L. Clinical factors and diagnoses associated with inappropriate urine culture ordering in primary care. *Infect Control Hosp Epidemiol*. 2026 Jan;47(1):80-87. doi:10.1017/ice.2025.10235. Epub 2025 Oct 21. PMID: 41117126; PMCID: PMC12825956.

Collazo A, Wermuth P, Luna Rodriguez J, Olmeda K, Mancera A, Faustinella F, Paasche-Orlow MK, Zoorob R, Trautner BW, Grigoryan L. ‘In Texas, everybody wants antibiotics’: reducing inappropriate antibiotic expectations and use with a provider-patient communication tool in primary care. *Fam Med Community Health*. 2025 Nov 11;13(4):e003628. doi:10.1136/fmch-2025-003628. PMID: 41218913; PMCID: PMC12606499.


Rajvong WP, Robinson W, Nguyen J, Walther CAP, Zoorob R, Hirth JM. The Impact of Flooding and COVID-19 on Access to Health Care and Services in Houston: Results from a Community Survey Study. *Disaster Med Public Health Prep*. 2026 Mar 26;20:e64. doi:10.1017/dmp.2026.10329. PMID: 41883261.

Collazo A, Haltom TM, Luna Rodriguez J, Olmeda K, Mancera A, Faustinella F, Paasche-Orlow MK, Landis-Lewis Z, Zoorob R, Trautner BW, Grigoryan

L. Patient and healthcare professionals’ perceptions of educational tools to reduce urine culture contamination in outpatient clinics: a qualitative study. *Antimicrob Steward Healthc Epidemiol*. 2026 Mar 9;6(1):e57. doi:10.1017/ash.2026.10317. PMID: 41822787; PMCID: PMC12975624.

Kim-Vences SIH, Nguyen J, Hirth JM, Suen KP, Keough CA, Zoorob R, Kowalchuk AA. Training in medications for opioid use disorder and buprenorphine prescribing in the post X-waiver era: Insights from a nationwide, multispecialty survey. *Prev Med*. 2026 Feb;203:108485. doi:10.1016/j.ypmed.2025.108485. Epub 2025 Dec 8. PMID: 41371368.

Collazo A, Grigoryan L, Jiang C, Zoorob R, Trautner BW, Skelton F. Physiologic Differences in Vital Signs and Urine Tests in Spinal Cord Injury and the Effects on Urinary Tract Infection Diagnosis. *Am J Phys Med Rehabil*. 2026 Feb 1;105(2):97-103. doi:10.1097/PHM.0000000000002820. Epub 2025 Aug 11. PMID: 40856495.



Make a Gift

Your gift to the Lung Institute will help pioneer new procedures and technologies, advance medical research, improve the quality of patient care and train the next generation of surgeons, educators and innovators. Thank you for your generosity.



Baylor
College of
Medicine

LUNG
INSTITUTE